Cirrhosis

Cirrhosis is the late stage of chronic liver disease, in which repeated injury leads to diffuse fibrosis and the formation of regenerative nodules. These changes distort the liver's architecture and its blood supply, so the organ loses much of its capacity to synthesize proteins, detoxify blood and regulate metabolism. The most common causes are chronic hepatitis B and hepatitis C infection, alcohol-related liver disease, and metabolic fatty liver disease linked to obesity and diabetes. Cirrhosis is a leading cause of illness and death worldwide, and it is also a major driver of liver cancer.

The disease is clinically important because it often progresses silently in its compensated phase and then becomes life-threatening once decompensation occurs, with ascites, hepatic encephalopathy, variceal bleeding or jaundice. Management therefore has three aims: removing or controlling the underlying cause, preventing and treating complications, and identifying patients who need liver transplantation. Prognostic scores such as Child–Pugh and MELD guide these decisions.

This entry explains the pathology and causes of cirrhosis, the cellular mechanisms that drive fibrosis, and its natural history. It then covers the main complications, including portal hypertension and its consequences, and describes diagnosis, staging, treatment, transplantation and emerging therapies. It closes with epidemiology, prevention and the history of the concept.

Definition and pathological features

Chronic liver injury that persists into its final stage produces cirrhosis, a state of continuous inflammatory activity that has left the organ permanently scarred Liver cirrhosis is the final stage of continuous hepatic inflammatory activity derived by viral, metabolic or autoimmune origin. The 1977 morphological criteria from a World Health Organization expert group required a process that was diffuse, evidence of necrosis, nodular regeneration alongside fibrosis, and distortion of normal architecture with vascular change In 1977, experts from the World Health Organization (WHO), based on morphological data, considered the following criteria: 1. That the process be diffuse to exclude local or focal lesions; 2. That there is necrosis, which excludes congenital hepatic fibrosis; 3. There must be nodular regeneration and diffuse fibrosis, excluding regenerative nodular hyperplasia; 4. There must be distortion of the architectural pattern and vascular alteration. These criteria separate cirrhosis from look-alike conditions. Fibrosis without regenerative nodules, and nodules without fibrosis, are not true cirrhosis Incompletely formed liver nodules, nodules without fibrosis (nodular regenerative hyperplasia), and congenital hepatic fibrosis (ie, widespread fibrosis without regenerating nodules) are not true cirrhosis. Simple fibrosis, therefore, is an earlier point on the same path rather than an equivalent condition. Fat accumulation is not part of the definition either, since it may appear in a cirrhotic liver without defining it Sometimes, cirrhotic livers have fatty accumulation which makes the liver more pale and yellow compared to the normal rich red/brown.

Histological staging

On the METAVIR fibrosis scale, cirrhosis occupies the highest category, F4, which clinicians then divide into compensated and decompensated phases The cirrhotic stage (METAVIR F4) is broadly classified into 2 stages: compensated and decompensated, with clinical decompensation being defined by the development of ascites, variceal hemorrhage, encephalopathy, and jaundice. Some pathology schemes subdivide stage 4 further by the thickness of the septa and the number of nodules, from mild cases with mostly thin septa to severe cases with very broad septa or many small nodules 4A: mild cirrhosis; marked septation with rounded contours or visible nodules; most septa are thin (1 broad septum allowed) 4B: moderate cirrhosis with at least 2 broad septa 4C: severe cirrhosis with at least 1 very broad septum or many minute nodules

The nodular pattern is classified by nodule size. Micronodular cirrhosis has uniformly small nodules (< 3 mm in diameter) and thick regular bands of connective tissue. Macronodular cirrhosis has nodules of varying size, from about 3 mm up to 5 cm, surrounded by broad fibrous bands The nodules vary in size (3 mm to 5 cm in diameter) and have some relatively normal lobular organization of portal triads and terminal hepatic venules. Broad fibrous bands of varying thickness surround the large nodules. A mixed pattern contains both sizes. The pattern carries clues about cause. Micronodular change is seen in cirrhosis due to alcohol, hemochromatosis, hepatic venous outflow obstruction, chronic biliary obstruction, jejunoileal bypass, and Indian childhood cirrhosis. Macronodular change is more typical of hepatitis B and C, alpha-1 antitrypsin deficiency, and primary biliary cholangitis. The two patterns are not fixed. Some liver diseases such as alcoholic liver disease may present as micronodular cirrhosis and develop larger nodules with subsequent regeneration of hepatocytes. For this reason, the morphological classification is considered not as clinically useful as etiologic classification.

Loss of hepatic function

Scarring replaces functional tissue, so the organ tend[s] to be smaller due to loss of hepatocytes and stiffer due to the presence of fibrotic scar tissue. The shrinkage has a functional cost. Because the mass of working hepatocytes falls, the liver's synthetic, detoxifying and metabolic capacity declines in parallel, and this loss of capacity is the root of the clinical failure seen in later stages Cirrhosis of the liver is a chronic disease of the liver characterized by the replacement of normal tissue with fibrous tissue and the loss of functional liver cells.

Intrahepatic resistance to portal flow

The structural changes also obstruct blood flow through the organ. Regenerative nodules can press on the hepatic veins and impede drainage In addition to decreased liver function, portal hypertension results from the obstruction of liver blood flow secondary to regenerative nodules impinging on the hepatic veins. Vascular tone also rises. In cirrhosis, endothelin-1 production and receptor sensitivity increase while nitric oxide production falls, which leads to increased intrahepatic vasoconstriction and resistance, initiating portal hypertension. Contraction of stellate cells that line the sinusoids adds to this, since vascular remodeling mediated by the contractile effects of HSCs in the sinusoids augments the increase in vascular resistance. Portal pressure depends on both the volume of inflow and the resistance that blood meets inside the liver Portal pressure is the product of the portal flow and intrahepatic resistance. Portal hypertension is therefore driven by changes in both variables, and the intrahepatic component is the structural basis for the later hemodynamic complications PH is the result of changes in both intrahepatic resistance and portal flow.

Causes and risk factors

Cirrhosis is a common endpoint rather than a single disease, and its causes vary with geography, economic conditions and the period studied. Chronic viral hepatitis has long been the largest source of cases in many regions. Viral hepatitis is the dominant cause in China. Vaccination and effective treatment have reduced infection numbers, but the remaining population is still large enough to keep viral disease a major driver there but the overall number is still large. In much of the Middle East and Africa, hepatitis C remains the main etiology particularly HCV. Hepatitis B and hepatitis C differ in how they respond to treatment. Direct-acting antivirals can clear hepatitis C in most treated patients, and this has shifted the balance of causes. With the advancements in treatment and the possibility for a cure of HCV infection, the paradigm has shifted more towards NAFLD and alcohol use as the main causes of cirrhosis. Cure does not remove all risk, because patients with established fibrosis can still develop hepatocellular carcinoma. Hepatitis B is harder to eradicate. Long-term nucleos(t)ide analogue therapy suppresses viral replication and slows progression, but it rarely clears the viral DNA reservoir in hepatocytes, so most patients need continued treatment. A prospective cohort found that among people with chronic hepatitis B or C who had received antiviral therapy, the presence of metabolic steatosis carried a higher adjusted hazard of cirrhosis, suggesting that MASLD's role may become more prominent after viral control or eradication.

Alcohol-associated liver disease (ALD) is driven by cumulative exposure. Epidemiological reviews associate daily alcohol consumption (as opposed to intermittent binge drinking), amount of alcohol consumed, longer duration of alcohol abuse, and being female with a higher risk of cirrhosis. A commonly cited estimate is that the consumption of 40 g per day for 10 years is associated with an increased risk of cirrhosis. Sex strongly modifies this threshold. In a meta-analysis of more than two million people, consumption of one to two drinks per day as compared with long-term alcohol abstinence was associated with an increased risk of liver cirrhosis in women, but not in men. Women show higher risk at every level of intake. Biological explanations include lower enzyme activity in women: the baseline enzymatic activity is lower than in men, thus leading to a higher alcohol toxicity and liver injury. Smaller body water content also produces higher blood alcohol concentrations after the same dose. In a Scandinavian case-control study, the odds ratio increased from 1.0 to 31.4 in men drinking more than 100 g/day of alcohol, and from 2.2 in abstaining women to 44.8 in women drinking more than 100 g/day. Coexisting factors matter as well. The same study reported that alcohol intake, chronic hepatitis B and C virus infections, and the risk of liver cirrhosis were each independently associated with cirrhosis.

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease (NAFLD), is now the most rapidly growing cause. The term non-alcoholic steatohepatitis (NASH) will officially be replaced by metabolic dysfunction-associated steatohepatitis (MASH), while nonalcoholic fatty liver disease (NAFLD) will now be called metabolic dysfunction-associated steatotic liver disease (MASLD). The renaming was intended to reduce stigma and to name the main driver more accurately. The diagnosis now requires the presence of hepatic steatosis plus at least one of five cardiometabolic risk factors. The shift in epidemiology is substantial. In a study of US veterans, the leading cause of cirrhosis among United States veterans has shifted from viral hepatitis to steatotic liver disease (SLD). Prevalence as a cause varies widely between countries. Reported figures range from 2% in South Korea and Brazil to 18% in Canada. Pathogenesis is closely tied to obesity, insulin resistance and type 2 diabetes. The consensus framework reflects the role that metabolic dysfunction related to insulin resistance plays in the pathogenesis of this multisystemic disease. Patients who also drink alcohol above specified thresholds fall into a separate category, MetALD. For individuals with steatosis who have at least one cardiometabolic risk factor and use alcohol >20 gm daily for females, and >30 gm daily for males, the classification is known as MetALD. Because these categories overlap, steatotic liver disease is now used as an umbrella term.

Other causes are less common but important, and they are often identified because they are treatable. Autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis cause immune-mediated injury of hepatocytes or bile ducts. Hereditary disorders include hemochromatosis (iron overload), Wilson disease (copper overload) and alpha-1 antitrypsin deficiency, in which misfolded protein accumulates in hepatocytes. Some medications, including methotrexate and amiodarone, and certain toxins can cause chronic injury and fibrosis. Congestive hepatopathy, which develops with right-sided heart failure or constrictive pericarditis, causes chronic sinusoidal congestion and can eventually lead to fibrosis. In one South American series, viral causes accounted for 19.8% of cases, autoimmune liver diseases for 18%, and ALD alone for 16.3%.

When standard evaluation identifies no cause, the condition is termed cryptogenic cirrhosis. Current classifications recognize a cryptogenic category within steatotic liver disease, which includes Cryptogenic SLD as one of five groups. Many patients have more than one contributing factor, and these causes may sometimes overlap. In the same South American series, MASLD-related causes featured in 39.3% of patients when all combinations were included. Identifying every coexisting driver is therefore important, because each one may independently affect progression and treatment choice.

Pathogenesis: from liver injury to fibrosis and nodules

Cirrhosis begins with injury to hepatocytes. Viral infection, alcohol, fat accumulation and toxins all kill liver cells through apoptosis and necrosis, and the debris and danger signals released by dying cells draw in innate immune cells. The most important of these are the liver's resident macrophages, the Kupffer cells. Chemokine signaling such as CXCL6 can prompt Kupffer cells to release TGF-β1, which links the immune response directly to the fibrotic one. Infiltrating neutrophils and lymphocytes add to the cytokine load, so the injury becomes sustained rather than self-limiting. Fibrosis is thus the excessive accumulation of extracellular matrix proteins, including collagen and fibronectin, in response to persistent inflammation and cell death.

Stellate cell activation and matrix deposition

In a healthy liver, the main matrix-producing cells are the hepatic stellate cells. They store retinyl esters in cytoplasmic lipid droplets, make up roughly 10% of resident liver cells, and remain quiescent and non-proliferative when the liver is healthy. After repeated injury, these cells change from quiescent vitamin A-storing cells into proliferative myofibroblasts. Activated myofibroblasts then produce large amounts of collagen type I and alpha-smooth muscle actin, so the normal space of Disse fills with scar-forming matrix.

The central profibrogenic signal is transforming growth factor-β (TGF-β). Through SMAD-dependent and other pathways, it drives stellate cells toward the myofibroblast phenotype, increases matrix synthesis and shapes immune responses. The same cytokine plays a more ambiguous role in the healthy liver, where it restrains cell growth and promotes apoptosis during development and regeneration. When chronic injury keeps TGF-β levels high, however, it sustains stellate activation and contributes to extensive hepatocyte death, a shift that pushes the balance toward fibrosis. Work on TGF-β1 has also shown feedback loops in which the signal and its receptor-associated partners reinforce one another, which helps explain why fibrogenesis can persist after the initial trigger has weakened.

Regenerative nodules and septa

Fibrosis alone does not make cirrhosis. The defining step is the formation of regenerative nodules. Surviving hepatocytes keep dividing to replace lost tissue, and the growing islands of parenchyma become enclosed by collagen-rich bands. Vascularised fibrotic septa link portal tracts to each other and to central veins, so hepatocyte islands end up surrounded by septa and no longer contain a central vein. This loss of normal lobular architecture is the structural change that later restricts portal blood flow. Other injury patterns can show a similar outcome, and regenerative nodules and fibrous septae are the features that most consistently characterize the established disease.

Vascular remodeling and capillarization

The sinusoidal endothelium is altered early in the process. Normally the endothelial cells of the sinusoids are fenestrated, which allows free exchange between blood and hepatocytes. Liver injury leads to endothelial dysfunction, with loss of fenestrae and deposition of a basement membrane, a process known as capillarization. This creates a physical barrier between blood and parenchyma and adds to intrahepatic resistance. Capillarization may begin before much fibrosis has formed, and injury also produces vasoconstriction and angiogenesis within the sinusoids. Vascular injury can also be self-propagating: one proposed model describes sinusoidal endothelial injury, fluid translocation and vascular compression leading to obstruction of the hepatic veins, a sequence that produces the congestion seen in many cirrhotic livers.

The injury-repair cycle and modifying factors

Cirrhosis progresses through a cycle in which each round of cell death provokes repair, and the repair produces more matrix and altered vessels that in turn make the next insult more damaging. Because the process is driven by ongoing inflammation, removing the cause often slows it. Unchecked fibrosis can progress to cirrhosis and eventually to liver failure from portal hypertension, although fibrosis is reversible if the source of injury is removed. The speed of progression varies widely between individuals. Sex, age, inherited genetic variants and metabolic comorbidities such as obesity and diabetes are all recognized as modifiers of how quickly this cycle advances, although the relative weight of each factor differs by cause and is not fully quantified.

Natural history: compensated and decompensated phases

The compensated phase

Clinicians usually describe the course of cirrhosis as a silent stretch followed by an overt phase. The silent stretch is called compensated disease, and it is defined by the absence of jaundice, ascites, variceal bleeding and encephalopathy. A compensated state can persist for years in many patients, particularly when overall health is well managed. Silence does not mean stability, however. Altered liver architecture, rising portal pressure, systemic inflammation and hemodynamic changes accumulate during this period and raise the risk of a clinical event. (Its natural history is characterized by an asymptomatic phase, termed 'compensated' cirrhosis; Cirrhosis can remain compensated for many years.; As LC progresses over time, patients develop a variety of risk factors, including altered liver architecture, portal hypertension (PHT), systemic inflammation, and haemodynamic alterations that increase the risk for clinical decompensation.)

Decompensation events

The shift to the decompensated phase is marked by the first appearance of ascites, portal hypertensive gastrointestinal bleeding, hepatic encephalopathy or jaundice. Each of these reflects either the consequences of raised portal pressure or the failure of hepatic function, and the emergence of any one of them defines the transition. Ascites is typically the first sign of decompensation in most studies. Of these events, ascites is the most common first decompensation, and its development is followed by the more serious complications described in later sections on variceal bleeding and hepatic encephalopathy. Decompensation can also cluster: gastrointestinal bleeding, renal impairment, hepatopulmonary syndrome and sepsis can each accelerate the course of the disease, and hepatocellular carcinoma can do so at any stage.

Rates of transition and prognosis

The rate at which patients move from the compensated to the decompensated phase has been estimated at about 5–7% per year. Transition from a compensated to a decompensated stage occurs at a rate of ∼5–7% per year. The gap in survival between the two phases is large. The first decompensation in CLC patients is regarded as a prognostic watershed due to a substantial reduction in median survival from 10-12 years in CLC to only 1-2 years in DLC. In one cohort, the one-year survival was 95% among compensated patients compared with 61% among decompensated patients. Decompensation at the time of diagnosis also carried a relative risk of about 2.6 for death relative to compensated patients. Most deaths among people with compensated cirrhosis occur only after they have progressed to the decompensated stage. Hospital admissions are correspondingly dominated by non-elective presentations of decompensation, which consume substantial health-system resources. Quality of life also declines as complications accumulate, though the degree varies widely between individuals.

Acute-on-chronic liver failure

Acute-on-chronic liver failure (ACLF) describes a sudden deterioration in a patient with pre-existing chronic liver disease, and it is more severe than ordinary acute decompensation. ACLF is defined by organ failures (OFs) and is distinct from simple 'acute decompensation' (AD) of cirrhosis. The EASL-CLIF framework assesses failure of six systems (liver, kidney, brain, coagulation, circulation and respiration) using a modified sequential organ failure score. The central pathophysiological mechanism in the development of ACLF is intense systemic inflammation, which distinguishes this syndrome from AD. The prognostic gap is substantial: it is associated with a 28-day mortality rate of 20% or more (vs. 5% or less among patients with acutely decompensated cirrhosis without ACLF).

Definitions remain inconsistent. The APASL criteria set a bilirubin threshold of 5 mg/dL, while EASL-CLIF uses 12 mg/dL for liver failure in decompensated cirrhosis. Precipitants also differ by region: alcohol-related liver disease predominates in Western series, whereas hepatitis B-related ACLF is most common in China. In the EASL-CLIF CANONIC study, bacterial infection (32.6%), active alcohol use (24.5%), and GI bleeding (13.2%) as the main precipitants.

Reversibility

Cirrhosis was once regarded as an irreversible endpoint. That view has changed. Although fibrosis was previous thought to be an irreversible process, recent evidence convincingly demonstrated resolution of fibrosis in different organs when the cause of injury is removed. The liver's regenerative capacity makes regression more achievable there than in other tissues, and this has been documented in patients treated for hemochromatosis with phlebotomy, and after successful suppression and eradication of chronic hepatitis B and C infections. Mechanistically, regression involves reabsorption of scar, loss of collagen-producing myofibroblasts and activated hepatic stellate cells, and degradation of extracellular matrix. In a long-term study of patients with hepatitis B, histologically proven progressive reduction in necroinflammation and fibrosis scores occurred in most treatment-responsive patients with advanced fibrosis or cirrhosis.

Complete reversal of established nodular cirrhosis is much less well supported. Regression of fibrosis is not the same as reversal of cirrhosis, because vascular abnormalities persist in livers with regressed fibrosis. Underlying genetic changes also remain, since the driver mutations within hepatocytes persist even when fibrosis is seen to regress. Mature scars resist resolution: in an experimental model, the more mature scars, however, failed to resolve completely even after a prolonged period. Regression also cannot be assumed for every patient, and there is still a great percentage of patients whose disease does not regress or even progresses. Although the exact point at which fibrosis becomes irreversible is still unknown, reversion is usually achieved at the early stages of cirrhosis, and the nodular architecture of advanced disease is rarely restored.

Clinical presentation and physical signs

Cirrhosis usually declares itself slowly and in nonspecific ways. Early symptoms are usually milder and may include fatigue, diminished appetite, nausea and/or vomiting, and unexpected weight loss. Patients also commonly report swelling in the legs, feet or ankles and easy bruising or bleeding. Recognizable symptoms tend to emerge only as hepatic function declines (3-4), so the early picture is often a vague sense of being unwell rather than a single clear complaint.

The reason many patients are not diagnosed early lies largely in the compensated phase, which is typically silent. Often, cirrhosis shows no signs or symptoms until liver damage is extensive. In practice the disease is frequently found by accident. Often, it is discovered by chance when an abdominal ultrasound exam is done or blood is drawn for another reason. Some laboratory changes can precede any clinical symptom: fewer white blood cells and platelets in your blood can be the first sign of cirrhosis. A low platelet count therefore deserves attention even in a patient who feels well.

On examination, clinicians look for several characteristic findings. These include an enlarged liver or spleen, excess breast tissue (in men), a swollen abdomen as a result of too much fluid, swollen legs, reddened palms, red spider-like blood vessels on the skin, small testicles (in men), widened veins in the abdominal wall, and yellow eyes or skin. Two of these have specific appearances. Spider angiomas are small red lesions with fine vessels radiating from a central point, and palmar redness is seen across the palms. Clinicians also check for a fine tremor by having the patient hold their outstretched hands. The skin and eye yellowing of jaundice reflects bilirubin accumulating in the blood when the liver can no longer process it efficiently. The vascular and sex-hormone changes are generally attributed to impaired hepatic clearance of estrogens together with reduced androgen production, which explains why gynecomastia and testicular shrinkage occur in men and menstrual disturbance occurs in women. Portal hypertension can cause the spleen to trap white blood cells and platelets, and the resulting enlargement is known as splenomegaly. Less often, clubbing of the fingers, in which the fingertips spread out and become rounder than usual, is seen.

Several symptoms that are common in cirrhosis are not usually life-threatening, but they strongly affect quality of life and are often managed poorly. Itching is the most frequent of these; itchy skin, with no visible rash, is typical, and pruritus is managed with moisturizers and antihistamines, though many treatments show limited success. Muscle cramps are involuntary, painful contractions of skeletal muscles that can occur at rest or be intense enough to awaken a person from sleep. Their prevalence is high: muscle cramps affect up to 68% of patients, and they can disturb sleep and physical function. Sleep problems are also widespread, and insomnia and excessive daytime sleepiness afflict up to 80% of patients. Sexual dysfunction is frequently overlooked. In men, erectile dysfunction, loss of sex drive and shrinkage of the testicles are common. In women, low sex drive, painful intercourse, inability to reach orgasm and lack of ovulation may occur. Women also may lose their periods, even when they're not in menopause.

Late presentation is a major problem in cirrhosis care. In one retrospective cohort of 476 patients, half of the patients (50.0%) already had decompensated cirrhosis at baseline. Patients with alcohol-related liver disease usually presented at later stages of liver disease with higher Child-Pugh and MELD scores. Diagnosis often follows an incidental finding rather than symptoms: the diagnosis of liver disease is often made after laboratory or radiographic abnormalities are noted and further investigated, such as mildly elevated liver enzymes, thrombocytopenia, or coagulopathy. Because the compensated stage is silent, compensated cirrhosis is asymptomatic and thus often underdiagnosed until decompensation occurs. Among decompensating events, ascites is the most common and regularly the first decompensation event, and it is frequently the event that finally brings patients to medical attention.

Portal hypertension

Portal hypertension is a pathological rise in pressure within the portal venous system, and in cirrhosis it arises from two overlapping changes. The first is resistance to blood entering the liver. Most of the increased resistance comes from distorted liver architecture, namely fibrosis and regenerative nodules, but about a third comes from intrahepatic vasoconstriction. That constriction reflects activated stellate cells and contracting myofibroblasts, and it responds to vasodilators. The second is inflow. Increased splanchnic blood flow also worsens and maintains portal hypertension. Most accounts treat the rise in hepatic resistance as the trigger, with the later increase in portal inflow sustaining the elevated pressure.

Portal pressure is usually estimated by the hepatic venous pressure gradient (HVPG), which is the difference between the wedged and free hepatic venous pressures. It is measured with a balloon catheter passed through the jugular vein or another venous access route. In healthy individuals the value typically falls between 2 and 5 mmHg; a value of 5 mmHg or more indicates portal hypertension, and 10 mmHg or more defines clinically significant portal hypertension (CSPH). Readings between 6 and 9 mmHg are generally regarded as subclinical. At 12 mmHg or above, the level is also associated with a risk of variceal bleeding. Because the test is invasive and not widely available, the presence of esophageal or gastric varices and a low platelet count, associated with splenomegaly, have been considered surrogate markers. In treated patients, a fall in HVPG of 20% or more, or to below 12 mmHg, after β-blocker therapy is associated with a markedly lower risk of bleeding, ascites and spontaneous bacterial peritonitis.

Portosystemic collaterals form as the body's response to obstructed portal flow. These vessels open and dilate from preexisting channels that connect the portal venous system with the superior and inferior vena cava. They divert blood past the liver, but they do not fully relieve the pressure. Even when portal blood flow is entirely diverted through collaterals, portal hypertension persists because portal venous inflow continues to rise as a result of splanchnic vasodilatation, which is largely mediated by nitric oxide. The most clinically consequential collaterals are the esophageal and gastric varices, whose rupture is a leading cause of bleeding in cirrhosis.

Splenic enlargement is one of the earliest visible consequences of the raised portal pressure. Splenomegaly is found in 36–92% of patients with cirrhosis, and 11–55% have the clinical syndrome of hypersplenism, defined as splenomegaly together with a reduction in one or more cellular elements of the blood. Hypersplenism is distinct from splenomegaly alone: it describes a functional syndrome in which an enlarged spleen causes cytopenias through pooling and or destruction of blood cells. Thrombocytopenia is the most frequent manifestation, because platelets are most sensitive to splenic sequestration, while leukopenia, especially neutropenia, is less common. Normally approximately 30% of the total platelet mass exists as an exchangeable pool in the spleen, and in hypersplenism that pooled fraction grows. Thrombocytopenia from hypersplenism does not produce a proportional defect in hemostasis, because the total platelet count largely stays the same and is instead redistributed. Leukopenia arises from increased destruction or sequestration of leukocytes, and the anemia seen in these patients is a further contributor. Reduced hepatic production of thrombopoietin, a hormone that stimulates platelet formation, adds to the low count in cirrhosis. Management of severe thrombocytopenia with bleeding may involve splenectomy or partial splenic embolization, and TIPS does not correct thrombocytopenia. Cytopenias can improve when the underlying cause is treated; in one multicenter study of patients with hepatitis C cirrhosis, thrombocytopenia and leukocytopenia improved 4 weeks after direct-acting antiviral therapy, with thrombocytopenia showing further gradual improvement over the next year.

Ascites, spontaneous bacterial peritonitis and hepatorenal syndrome

Ascites: pathophysiology, classification and management

Ascites, the accumulation of free fluid in the peritoneal cavity, is the most common decompensating complication of cirrhosis. The 2021 AASLD guidance notes that roughly 5–10% of patients with compensated cirrhosis develop ascites each year, and that its appearance lowers five-year survival from about 80% to about 30%. The mechanism follows from portal hypertension. Splanchnic arteriolar vasodilation, driven largely by nitric oxide and other vasodilators, reduces the effective arterial blood volume. The kidneys respond by retaining sodium and water, and the renin–angiotensin–aldosterone system, the sympathetic nervous system and antidiuretic hormone secretion all sustain this retention. Fluid leaves the sinusoids and splanchnic lymphatics and collects in the peritoneum, so the body's salt and water stores keep expanding even as the effective circulation remains underfilled.

Ascites is graded by volume, from grade 1 (detectable only by imaging) to grade 3 (large or tense). It is also classified by diuretic response. Ascites is considered refractory when it cannot be mobilized, or when it recurs early after treatment, because of diuretic resistance or diuretic-induced complications that prevent an effective dose. The International Ascites Club separates these as diuretic-resistant and diuretic-intractable forms. Refractoriness develops in roughly 5–10% of patients with ascites. Every patient with new-onset ascites, worsening distension or suspected infection should have a diagnostic paracentesis, since the ascitic fluid analysis guides both infection and etiology assessment.

First-line management relies on dietary sodium restriction, usually to about 2 g (88 mmol) per day, combined with aldosterone-antagonist-based diuretic therapy. Patients who do not respond need repeated large-volume paracentesis (conventionally more than 5 L), with intravenous albumin given at about 6–8 g per liter removed. Albumin is the most effective measure for preventing post-paracentesis circulatory dysfunction, and the EASL guidance favors it over other plasma expanders. Removal of very large volumes, particularly above 8 L, carries a risk of circulatory shifts. In selected patients, a transjugular intrahepatic portosystemic shunt (TIPS) is an alternative that is discussed in the sections on portal hypertension and transplantation.

Spontaneous bacterial peritonitis

Spontaneous bacterial peritonitis (SBP) is an infection of ascitic fluid without a surgically treatable intra-abdominal source. It is diagnosed when the ascitic fluid neutrophil count reaches about 250 cells per cubic millimeter or more, with the cell count, culture and protein measurement interpreted together. Patients typically present with abdominal pain, fever or encephalopathy, but many are only mildly symptomatic, so a low threshold for paracentesis is needed in hospitalized patients with ascites. Treatment consists of intravenous third-generation cephalosporins, with albumin given to patients who have raised bilirubin, creatinine or urea, as this reduces the risk of renal failure and death.

Prophylaxis is directed at high-risk patients. Long-term oral norfloxacin or ciprofloxacin is recommended after a previous episode of SBP. Single-dose or short-course ceftriaxone is used during gastrointestinal bleeding, and primary prophylaxis is considered in patients whose ascitic fluid protein is low (below about 1.5 g/dL) and who also have renal dysfunction or advanced liver failure. The 2021 guidance emphasizes that rising antimicrobial resistance has changed the choice of prophylactic agents, which is why the older regimens are now reconsidered in each population.

Hepatorenal syndrome

Hepatorenal syndrome (HRS) is a functional form of kidney failure that occurs in advanced cirrhosis with ascites. The kidneys show no structural injury, and the condition reflects intense renal vasoconstriction in response to the circulatory changes described above. It is a diagnosis of exclusion. The International Ascites Club criteria require cirrhosis with ascites, acute kidney injury meeting defined creatinine criteria (a rise of at least 0.3 mg/dL within 48 hours, or at least 50% above baseline), and no sustained improvement after at least two days of diuretic withdrawal and albumin challenge (typically 1 g/kg per day). In addition, shock, current or recent nephrotoxic drug exposure, and signs of structural kidney disease such as substantial proteinuria, microscopic hematuria or abnormal renal ultrasonography must be excluded. Because the criteria depend on repeated creatinine measurements, earlier diagnosis has been a focus of revision.

HRS is divided into type 1, a rapidly progressive form in which creatinine doubles within about two weeks, and type 2, which develops more slowly and is usually associated with refractory ascites. Type 1 carries the poorer prognosis. Treatment combines a vasoconstrictor with albumin. Terlipressin, a vasopressin analogue and the only agent approved by the US Food and Drug Administration for HRS with rapidly reduced kidney function, is the usual first choice when available. Norepinephrine, or midodrine with octreotide, are alternatives. Response is more likely when baseline creatinine is lower, which supports starting treatment as early as the criteria allow. Renal replacement therapy can bridge patients to liver transplantation, which remains the only definitive treatment for most patients with HRS.

Hepatic encephalopathy

Pathogenesis

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome caused by liver insufficiency and/or portosystemic shunting. The modern picture was first sketched in the 1890s, when Pavlov and Nencki's group showed that a portocaval shunt raised blood and brain ammonia and produced marked behavioral change. Gut bacteria generate ammonia from urea, a byproduct of protein digestion, and the liver converts that ammonia back to urea for excretion by the kidneys. In cirrhosis, impaired liver function reduces ammonia metabolism, which worsens hyperammonemia. Blood that bypasses the liver through a spontaneous or transjugular shunt raises ammonia further (the same is true of TIPS).

The brain itself has no effective urea cycle. Ammonia is instead removed in astrocytes, where glutamine synthetase, located almost exclusively in astrocytes, combines ammonia with glutamate to form glutamine. The resulting accumulation of glutamine draws water into astrocytes, causing swelling and cerebral edema, and the ammonia load also disturbs neurotransmission. One model proposes that the astrocytic handling of ammonia increases GABA-mediated inhibition, which lowers cerebral energy demand and may explain why the condition is usually reversible. Ammonia is not the whole story, however. Some patients with severe HE have normal ammonia concentrations, and ammonia administered to patients with cirrhosis in controlled trials did not reliably produce HE. Systemic inflammation is thought to be decisive: the blood–brain barrier is normally largely impermeable to ammonia, but systemic inflammation weakens it and allows ammonia to enter the central nervous system. Other contributors studied include manganese, hyponatremia and circulating TNFα, whose level correlates with HE severity in cirrhosis.

Precipitating factors

Most episodes of overt HE have an identifiable trigger. Recognized precipitants include constipation, gastrointestinal bleeding, infections, hyponatremia, and dehydration or diuretic overdose. Sedative drugs and high-protein intake are also implicated. In one series of 132 admissions for overt HE, infection was the most common precipitant (49.2%), followed by electrolyte imbalance (41%), constipation (33.3%) and gastrointestinal bleeding (16%). Infection, particularly spontaneous bacterial peritonitis, is therefore a key point for clinicians to exclude. Because precipitants are often correctable, treating them is considered the most important step in reversing an acute episode.

Clinical spectrum and grading

HE ranges from subtle to severe. The spectrum runs from overt HE (OHE) to minimal HE (MHE). The most widely used bedside scale is the West Haven system, which grades symptoms on a scale of 0 to 4. Grade 0 and grade I are covert stages. Grade I involves a trivial lack of awareness, a shortened attention span, euphoria or anxiety, and mild impairment in performing simple addition or subtraction. Minimal HE, which has no overt signs, is detected only by specialized psychometric or neurophysiological tests; the Psychometric Hepatic Encephalopathy Score is the established reference test (five paper-and-pencil tests). Overt HE begins at grade II, which is characterized by lethargy or apathy, disorientation to time, obvious personality changes, inappropriate behavior, and the presence of asterixis. Grades III and IV progress toward confusion and coma. Because of this variable clinical picture, the International Society for Hepatic Encephalopathy and Nitrogen Metabolism combined minimal HE and grade I into a single covert category (so that OHE can be uniformly diagnosed). Asterixis, an involuntary flapping tremor, is central to the grading, and it is clinically easier to detect than the earliest changes. Grade 1 asterixis may be present, but the grade II threshold is where West Haven grading becomes most reliable.

Treatment and prognosis

Treatment has two aims: correcting the acute episode and preventing recurrence. Lactulose and rifaximin are standards of care for preventing overt hepatic encephalopathy in patients with cirrhosis. Lactulose is the first-line agent, and for patients on lactulose monotherapy, there is a 40% cumulative risk of recurrent overt HE within 6 months of an initial episode. Adding rifaximin reduces this risk. Compared with lactulose alone, adding rifaximin significantly reduces the risk of overt HE recurrence and HE-related hospitalization without compromising tolerability. In a later trial presented in 2024, the incidence of an overt HE episode over 6 months was lower with rifaximin monotherapy (23.2% vs. 49%). Other options include intravenous L-ornithine L-aspartate and oral branched-chain amino acids, used as alternatives or additions for patients who do not respond to conventional therapy. Prophylaxis is generally continued unless precipitating factors such as infections and variceal bleeding have been well controlled, or liver function or nutritional status has improved.

Recurrence carries prognostic weight. Recurrent episodes drive hospital admissions; in one cohort, HE-related hospitalizations were significantly lower in the rifaximin group (12.7% vs. 30.5%). After TIPS, higher age and previous HE episodes were identified as risk factors for HE. Since HE is typically episodic, it is mostly episodic and therefore reversible, but each recurrence adds to the burden of disability and the risk of death.

Variceal bleeding and other gastrointestinal hemorrhage

Bleeding from dilated portosystemic veins is among the most dangerous complications of cirrhosis. Varices form in the submucosa of the lower esophagus and the upper stomach when collateral channels enlarge in response to raised portal pressure (portal hypertension). Bleeding occurs in 30%-40% of patients with cirrhosis and varices. Clinical care is usually divided into three phases: primary prophylaxis, control of the acute episode, and secondary prophylaxis against rebleeding.

Development and risk stratification

Esophageal varices are graded by size and by endoscopic appearance. Small varices with a longitudinal red mark, known as a red wale sign, indicate a higher risk of bleeding, and bleeding risk can be ascertained at the time of endoscopy by evaluating for the presence of these markers. Large varices and varices with red signs together form the high-risk group. Liver function, usually expressed as the Child–Pugh class, adds further prognostic information, with decompensated patients at greater risk. Gastric varices are classified separately by their anatomical location, and their treatment differs from that of esophageal varices. Noninvasive tests can exclude clinically significant varices in some patients. Patients with a liver stiffness under 20 kPa and a platelet count over 150,000/μL are at low risk of having varices requiring treatment, which can spare them a screening endoscopy.

Management of acute bleeding

Treatment starts before endoscopy. Upper GI bleeding in a patient with chronic liver disease or cirrhosis should be assumed to come from varices, and vasoactive treatment such as terlipressin or somatostatin/octreotide should be started at the earliest, preferably within 30 minutes. The vasoactive agent is generally continued for several days; one guideline recommends continuing until haemostasis is achieved or for up to 5 days. Empirical antibiotic therapy is standard. Ceftriaxone is the preferred antibiotic due to its coverage of gram-negative bacteria, and in advanced disease intravenous ceftriaxone (1 g/day) may be preferable particularly in centers with a high prevalence of quinolone-resistant organisms.

Endoscopy should follow promptly. One guideline advises EGD, performed within 12 hours, should be used to make the diagnosis and to treat variceal hemorrhage, either with EVL or sclerotherapy. Endoscopic band ligation (EVL) is preferred for esophageal varices because it achieves higher success with fewer adverse effects than sclerotherapy, while for gastric varices, the preferred initial modality of treatment is glue or thrombin injection. Transfusion should be restrictive: one guideline suggests keeping hemoglobin greater than 60–70 g/L, with allowance for cardiovascular disease, age and ongoing bleeding. Coagulopathy and thrombocytopenia are corrected only when clinically indicated, and platelet transfusion is not advised for patients who are stable and not bleeding.

When bleeding continues despite drugs and endoscopy, temporary tamponade with a balloon can bridge to definitive treatment, although the balloon tamponade is usually not kept for more than 24 h due to the risk of major complications. Transjugular intrahepatic portosystemic shunt (TIPS) is the main rescue option. In refractory bleeding, one guideline reports that very early TIPS (emergency TIPS) within 8 hours offers a better survival than TIPS beyond 8 hours. Salvage TIPS is generally avoided in patients with very advanced liver dysfunction; one review notes it should, however, be avoided in patients with a Child-Pugh score of more than 13.

Prophylaxis

Primary prophylaxis aims to prevent the first bleed. Nonselective beta-blockers (NSBB) and EVL are the two options. Propranolol is suggested as first line, with carvedilol or nadolol as alternatives. EVL is reserved for patients who cannot take NSBB, and the choice also reflects patient preference. For small varices without red signs, the benefit of beta-blockers is less certain, as their long-term benefit has not been established.

Secondary prophylaxis, started after a bleed has been controlled, combines an NSBB with repeated endoscopic ligation, which lowers rebleeding more than either approach alone. TIPS is considered for those who rebleed despite this combined therapy.

Portal hypertensive gastropathy and other sources

Bleeding is not always variceal. Portal hypertensive gastropathy causes diffuse mucosal changes in the stomach that can ooze blood chronically rather than in a single dramatic episode. Peptic ulceration and other lesions can also bleed in cirrhosis. The most common consequence of this slow loss is iron-deficiency anemia, which can be compounded by the low platelet counts caused by hypersplenism. Treatment of gastropathy includes NSBB therapy and iron replacement, with TIPS or endoscopic therapy reserved for severe, transfusion-dependent bleeding.

Hepatocellular carcinoma

Among the conditions that predispose to hepatocellular carcinoma (HCC), the cirrhotic liver carries the greatest weight, which is why surveillance is recommended for people with cirrhosis (Liver cirrhosis is the largest risk factor for developing hepatocellular carcinoma). Chronic hepatitis B and hepatitis C infections, which often progress to cirrhosis, are the other principal antecedents (Liver cirrhosis and chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are major risk factors). Globally, the tumor ranks among the leading causes of cancer death, and most cases arise in people with cirrhosis or chronic hepatitis B (HCC is a leading cause of cancer-related mortality worldwide, with most cases arising in patients with cirrhosis or chronic hepatitis B.). Annual incidence in cirrhosis is commonly quoted as roughly 1 to 8 percent, though published figures vary with cause and cohort (variable annual risk of 1-8%).

The molecular route is thought to run through chronic necroinflammation. Repeated hepatocyte death and compensatory proliferation within a fibrotic, regenerating liver raise the chance of acquiring oncogenic mutations and epigenetic changes, while the inflammatory milieu and Kupffer cell and lymphocyte dysfunction may allow precancerous cells to escape immune control. Recurrent alterations in the TERT promoter, CTNNB1 (β-catenin) and TP53 are among the frequently described events. Many tumors are thought to develop stepwise from regenerative and dysplastic nodules, which explains why nodules in a cirrhotic liver need follow-up imaging.

Major guidelines, including those of AASLD, EASL and APASL, recommend abdominal ultrasound every six months, with or without serum AFP, for at-risk adults (surveillance be performed using abdominal ultrasound, with or without AFP, every six months). Ultrasound is weakest where it matters most: in a meta-analysis of 32 studies, sensitivity was 84% for tumors of any stage but only 47% for early-stage disease (Thirty-two studies (comprising 13,367 patients) characterized sensitivity of imaging with or without AFP measurement for detection of HCC in patients with cirrhosis. Ultrasound detected any stage HCC with 84% sensitivity (95% confidence interval [CI] 76%–92%), but early-stage HCC with only 47% sensitivity). The same analysis found that adding AFP raised early-stage sensitivity to 63%, compared with 45% for ultrasound alone (Ultrasound with vs without AFP detected early-stage HCC with 63% sensitivity (95% CI 48%–75%) and 45% sensitivity (95% CI 30%–62%), respectively). AFP alone is not recommended for routine surveillance (Measurement of AFP alone is not recommended for routine surveillance). Earlier analyses judged AFP too imprecise to be useful, so the optimal strategy remains debated, and risk-stratified schemes have been proposed to address poor adherence and false positives (this one-size-fits-all approach has important limitations, including suboptimal sensitivity, frequent false-positive results, poor adherence). Diagnosis in a surveillance-detected nodule is usually made noninvasively: in cirrhotic livers, contrast-enhanced computed tomography or magnetic resonance imaging showing characteristic arterial enhancement and washout in a nodule above about 1 cm generally suffices, so biopsy is reserved for atypical lesions.

Treatment depends on tumor burden, liver function and portal pressure. The Milan criteria, introduced in 1996, limit transplantation to a single lesion up to 5 cm, or up to three lesions none larger than 3 cm, without gross vascular invasion or extrahepatic spread, and report a 4-year survival of about 75% within these limits (When liver transplantation (LT) is restricted to patients with early HCC, defined as a single lesion ≤5 cm, up to 3 separate lesions with none >3 cm, with no evidence of gross vascular invasion, and no regional nodal or distant metastases (known as the Milan criteria), a 4-year survival rate of 75% can be achieved.). Under the Barcelona Clinic Liver Cancer (BCLC) system, the 2022 update favors transplantation for multifocal tumors within Milan and does not recommend resection for multinodular disease within those limits (Multifocal disease still within the Milan criteria is better served by LT, as ablation and resection are hampered by a high risk of HCC recurrence. The 2022 version of the BCLC staging system does not recommend resection for multinodular HCC within Milan criteria.). For a single lesion with stable portal pressure and bilirubin, resection is preferred, while transplantation is favored when these are elevated (The BCLC group recommends LR for single lesions at an early stage with stable portal pressure and bilirubin. When portal pressure or bilirubin levels are elevated, the BCLC group recommends LT whenever possible.). Very small single tumors of 2 cm or less are generally treated with radiofrequency ablation in preference to resection (for very early-stage patients with a single HCC lesion within 2 cm, the BCLC group opted for RFA over LR). Transchemoembolization is the usual alternative when first-line options are infeasible, and selected intermediate-stage patients beyond Milan may still be considered for transplantation. Advanced disease is managed with systemic agents, such as combined immunotherapy with monoclonal antibodies or multikinase inhibitors, with the choice constrained by Child–Pugh class.

Recurrence is the main limitation of curative treatment. After resection or ablation, recurrence has been reported at 50–60% (these therapies are restricted by high rates of recurrence (50–60%)). Tumor size, AFP level, the presence of cirrhosis, microvascular invasion and antiviral treatment have all been identified as prognostic for recurrence (The tumor size, serum alpha-fetoprotein, presence of cirrhosis, microvascular invasion and administration of antiviral therapies have been identified as prognostic factors for recurrence after resection).

Antiviral therapy changes cancer risk substantially in viral cirrhosis. Direct-acting antivirals cure hepatitis C in about 95% of treated people and improve liver function (treatment with direct-acting antivirals (DAA) cures HCV infection in about 95% of people). In a meta-analysis, patients who achieved sustained virological response had far fewer tumors than non-responders, at 1.54 versus 7.80 cases per 100 person-years (HCC occurrence was significantly lower in CHC with SVR (1.54 per 100 person-years) than those in non-responders (7.80 py)). Cirrhosis remained a major modifier, with a rate after cure about three times higher than in people without cirrhosis (HCC risk following SVR occurred three times more frequently in patients with cirrhosis than patients without cirrhosis). Interferon-based and direct-acting regimens did not differ significantly in this respect (we found no significant difference in HCC occurrence risk following SVR between DAA and IFN therapies). In a cohort of people with HIV and advanced fibrosis, the annual probability fell from 0.81% in the first year to below 0.4% after three years (Annual probability of HCC declines over time and falls below 0.4% after 3 years.). Long-term suppression of hepatitis B with antiviral drugs likewise lowers, but does not abolish, the risk, so surveillance generally continues after viral control.

Other systemic complications

Cirrhosis affects organs far from the liver. Altered blood flow, circulating toxins and chronic inflammation reach the lungs, heart, skeletal muscle, bone and clotting system, and these complications often shape prognosis as much as the hepatic injury itself.

Pulmonary vascular complications

Dilated blood vessels within the lung are the defining lesion of hepatopulmonary syndrome (HPS), which leaves arterial blood poorly oxygenated. It affects up to 30% of patients with cirrhosis and portal hypertension and is associated with a more than doubled risk of mortality. The diagnosis rests on an elevated alveolar–arterial oxygen gradient, which is classically defined as greater than 15 mmHg on room air, or greater than 20 mmHg in patients over 64 years of age. Mediators released in response to liver injury or portal hypertension, including endothelin-1, TNF-alpha, cytokines, nitric oxide and carbon monoxide, are thought to contribute to the vasodilation. Liver transplantation is the only treatment that generally reverses HPS.

Portopulmonary hypertension (POPH) is a distinct problem. Where HPS mainly impairs gas exchange, POPH raises pulmonary arterial pressure, which can strain the right ventricle. Its prevalence in cirrhosis is reported inconsistently, from 2–8% of patients with cirrhosis in one review to 5–10 % in another. A hyperdynamic circulation, with high cardiac output and low systemic vascular resistance, is thought to raise shear stress on the pulmonary endothelium and promote vascular remodeling. Because both conditions are often silent, all liver transplantation candidates should be actively screened for the presence of these two complications. Mild to moderate POPH that responds to medical therapy may still permit transplantation.

Cardiac changes

Cirrhotic cardiomyopathy describes cardiac dysfunction that becomes apparent under stress rather than at rest. It is characterized by systolic dysfunction more evident under conditions of hemodynamic stress, impaired diastolic relaxation, and electrophysiologic alterations often manifesting with a prolonged QT interval. Because it is usually silent at rest, it is frequently not recognized. The 2005 World Congress of Gastroenterology criteria used a left ventricular ejection fraction below 55% or a blunted contractile response, together with diastolic indices. The 2019 Cirrhotic Cardiomyopathy Consortium criteria instead use an ejection fraction of 50% or less, or reduced global longitudinal strain, combined with at least three of the following: septal e′ velocity < 7 cm/s, E/e′ ≤ 15, left atrial volume index > 34 ml/m², and tricuspid regurgitation velocity > 2.8 m/s. The choice of criteria matters: in one cohort of 122 patients, overall prevalence of CCM was similar for the Montreal (67.2%) and CCC (55.7%) criteria; both were significantly higher than the ASE/EACVI criteria (35.2%). Splanchnic vasodilation, activation of the renin–angiotensin–aldosterone system and endotoxemia are among the proposed drivers. The inability to raise cardiac output is likely a cofactor in cirrhosis complications such as hepatorenal syndrome or shock. No specific treatment has been tested for this condition, so clinicians are advised to monitor closely during procedures such as TIPS, paracentesis and transplantation.

Sarcopenia, malnutrition and frailty

Sarcopenia, the generalized loss of skeletal muscle, and frailty, the decline in physiological reserve, are both common. Sarcopenia affects 40%-70% of patients with cirrhosis, and frailty affects 20%-50% of patients with cirrhosis with variations across populations and definitions. The drivers include hyperammonemia, systemic inflammation, endocrine disturbances, malnutrition and accelerated starvation, gut-liver-muscle axis alterations, mammalian target of rapamycin inhibition, and inactivity. Both conditions carry prognostic weight beyond the MELD score: they independently predict hepatic decompensation, hospitalizations, waitlist dropout, and mortality. Inactivity creates a feedback loop in which patients become weaker and more prone to falls and hospitalization, causing further inactivity. Supervised exercise has shown benefit, since exercise interventions in cirrhosis have been shown to improve muscle function and aerobic capacity without precipitating complications.

Hyponatremia, coagulation and bone

Hyponatremia develops when the kidney cannot excrete free water, largely because nonosmotic release of vasopressin follows a fall in effective arterial volume. Ascites and diuretic therapy frequently contribute, and a low serum sodium generally signals more advanced disease. Management centres on stopping diuretics where possible, restricting free-water intake and treating the precipitating cause, and its interaction with kidney function is a recurring concern in decompensated disease.

Coagulopathy in cirrhosis is a rebalancing rather than a simple deficiency. Synthesis of most clotting factors falls, which prolongs the prothrombin time, but levels of anticoagulant proteins fall alongside them. Splenic sequestration and reduced thrombopoietin production lower the platelet count, adding to bleeding risk. At the same time, stasis and endothelial change in the portal system favour thrombosis, including portal vein thrombosis, so bleeding and clotting risks can coexist in the same patient.

Reduced bone mineral density and osteoporosis are common, and they increase the risk of fracture. Contributing factors include hypogonadism, vitamin D deficiency, low physical activity, poor nutrition and cholestasis. Fractures add to disability and hospitalization, so bone density is an element of routine assessment in long-standing disease.

Diagnosis and noninvasive assessment

No single laboratory test establishes cirrhosis. Clinicians usually begin with a panel that covers liver enzymes, bilirubin, albumin, clotting time and a blood count, basic tests including complete blood count, ALT, AST, albumin, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, and PT/INR are typical. These results have clear blind spots. In early compensated disease, laboratory findings may be normal. Aminotransferases are a particular trap: researchers at MUSC reported that people with alcohol-related cirrhosis often have almost normal aminotransferase levels, so clinicians who rely only on this test may miss the diagnosis. patients with alcoholic cirrhosis have nearly normal levels of aminotransferases. Platelet counts and clotting times reflect the synthetic and hemodynamic consequences of the disease rather than its cause, and a complete blood count may reveal low platelet levels, which can indicate advanced liver disease. Blood tests also carry confounders; their interpretation can be unreliable at the extremes of age and in those with comorbid conditions (eg, systemic inflammation, hemolysis, active alcohol use).

Serum scores offer a cheaper way to screen for advanced fibrosis. The FIB-4 index is calculated from age, AST, ALT and platelet count. The AASLD recommends the use of the simple tests (eg, FIB-4) over complex biomarkers for the detection of advanced fibrosis, and its high negative predictive value is the main reason it is used for exclusion. The scores are uneven across the fibrosis scale: noninvasive tests are most useful in identifying patients with no to minimal fibrosis (F0) or advanced fibrosis (F3 to F4) and are less accurate at distinguishing early or intermediate stages of liver disease (F1 to F2). In patients with fatty liver disease, one study found poor agreement with VCTE and low sensitivity for FIB-4, which argues for alternative cutoffs or additional tests.

Transient elastography, which measures liver stiffness, is more accurate for ruling in and ruling out cirrhosis. VCTE determines liver stiffness based on the propagation of a shear wave through the liver. In a retrospective series of 93 patients with fatty liver disease, a 12.5 kPa cutoff for F4 fibrosis had 92% sensitivity, and values below this threshold excluded cirrhosis with 98% certainty. The same study found ultrasound elastography more accurate than FIB-4 at ruling out cirrhosis in that cohort. If the FIB-4 score is ≥ 2.67 and the LSM is high, the patient likely has cirrhosis. Variceal screening may be needed. Because no single noninvasive test or model developed to date can match the information obtained from actual histology, combined algorithms are common.

Ultrasonography is the usual first imaging step. It is specific, reliable, noninvasive, fast, and cost-effective, and its sensitivity for cirrhosis can reach about 91%. Surface nodularity is the most useful single sign, and it can be found even in early phases. Other supportive findings include coarse, heterogeneous echotexture, relative enlargement of the caudate lobe, and atrophy of the left lateral segment. Doppler assessment adds information on portal hemodynamics: retrograde flow from the periphery to the central area can suggest liver cirrhosis with portal hypertension. Splenomegaly and a dilated portal vein are indirect indicators of portal hypertension. Ultrasound has limits, since it may not detect very early liver scarring.

Computed tomography and magnetic resonance imaging are less sensitive for early disease, but they show the morphology of advanced disease well. CT and magnetic resonance imaging (MRI) generally are poor at detecting morphologic changes associated with early cirrhosis, but they can accurately demonstrate nodularity and lobar atrophic and hypertrophic changes, as well as ascites and varices in advanced disease. MRI findings reported in the literature include surface nodularity, heterogeneous enhancement, a small liver size, caudate lobe enlargement, splenomegaly, a decreased right-to-left-lobe-volume ratio, among others.

Histology remains the reference standard for staging, but it has practical limits. Reported sensitivity and specificity for an accurate diagnosis of cirrhosis and its etiology range from 80 to 100 percent, depending on the number and size of the histologic samples and on the sampling method. Sampling error is a recognized problem because the accuracy of liver biopsy can be affected by sampling errors and fibrosis heterogeneity within the liver itself. Biopsy is therefore reserved for cases where clinical, laboratory, and radiographic data are inconclusive, but suspicion of cirrhosis remains. Establishing the cause relies on serology and other tests. When aminotransferases stay raised, additional serologic studies should be performed to evaluate for various etiologies of cirrhosis, and the workup typically includes viral hepatitis screening, autoimmune markers and iron studies.

Prognostic scores and staging systems

Child–Pugh classification

The Child–Pugh score combines bilirubin, serum albumin, prothrombin time (or INR), ascites and hepatic encephalopathy. For each factor, you can receive either one, two or three points. The totals therefore run between five and 15. Thresholds are Class A: 5 to 6 points; Class B: 7 to 9 points; Class C: 10 to 15 points, with the classes corresponding to normal, reduced and severe liver dysfunction, respectively. Survival estimates attached to these classes vary between sources. One series reports 1-year survival of 100% for class A, 80% for class B and 45% for class C, whereas another gives a one- to five-year survival rate of 95 percent for class A. The score was adapted from Child's 1964 scheme by Pugh in 1973, and its weaknesses are well recognised: two of its five items are judgement-based, and the narrow 5–15 range may not adequately discriminate between patients with different severity within the same class.

MELD and MELD-Na

The Model for End-Stage Liver Disease was built from creatinine, international normalized ratio of prothrombin rate (INR), and bilirubin. Its allocation use in the United States began in 2002 and follows a "sickest first" principle. The sodium-adjusted version adds a term for serum sodium:

In the implementation used for allocation, sodium values are bounded to the range 125–137 mEq/L. The reasoning was that hyponatremia is an independent prognostic factor in patients with cirrhosis but was not included in the original MELD score calculation. This MELD-Na score was officially implemented for liver graft allocation in January 2016. Several limitations remain. Sodium values can shift with inter-laboratory differences and the potential variability of serum sodium concentration after simple therapeutic maneuvers, such as diuretic administration, plasma volume expansion, or hypotonic fluid infusion. MELD also does not adequately capture the severity of illness, such as hepatocellular carcinoma, hepatopulmonary syndrome, and portopulmonary hypertension, which is why exception points are used for these conditions. Sex-based differences have also been examined: the implementation of MELD created sex-based disparities for accessing LT which were not previously present. One proposed correction maps female MELD-Na scores onto the male distribution by matching quantiles, which converts the original female Organ Procurement and Transplantation Network (OPTN) score to the corresponding male score.

Clinical staging by compensation and decompensation

The Baveno consensus separates compensated or decompensated based on the absence or presence of related complications such as ascites, variceal bleeding, and/or HE. Age has been found to modify the risk of decompensation: in one multicentre cohort, decompensation occurred in 18.7% and 6.7% in the older (age ≥60 years) and younger (age <60 years) groups, and the investigators subsequently integrated age into the Baveno criteria. The Baveno VII group also defined recompensation, which has uniform criteria... based on (i) the removal of the aetiological factor in patients with ALD, HBV and HCV cirrhosis, (ii) the absence of decompensating events and (iii) a sustained improvement in hepatic synthetic function. Recompensation is uncommon: one analysis concluded that fewer than 10% of decompensated patients achieve recompensation, while expanded criteria identified a larger group, with mortality risk not significantly different between patients achieving recompensation and compensated patients.

Acute-on-chronic liver failure grading

Acute-on-chronic liver failure (ACLF) is graded in the EASL-CLIF framework by the number of failing organs: liver, kidney, brain, coagulation, circulation and respiration. Grade 1 includes a single kidney failure, or a single non-kidney failure accompanied by creatinine of 1.5–1.9 mg/dL and/or mild encephalopathy. Grade 2 denotes two organ failures, and grade 3 denotes three or more. Short-term mortality rises with grade. Other consortia, such as the Asian Pacific Association for the Study of the Liver (APASL) group, use somewhat different definitions, so ACLF grades are not directly interchangeable across studies. Organ-specific thresholds, such as those for kidney and coagulation failure, underpin the grading and are set out in the consortium publications.

Limitations and newer models

Existing scores differ in performance across etiologies and patient groups. Child–Pugh depends partly on subjective assessment, MELD omits several disease-specific risks, and sodium and creatinine can fluctuate with treatment. Because a single measurement captures only one moment, researchers have explored dynamic approaches that track how a patient's scores change over time, including the changes used to define recompensation. Other proposals include albumin-bilirubin grading and ACLF-specific models, and several sex-adjusted or revised MELD formulas have been proposed. Whether any of these outperform the established scores across all causes of cirrhosis remains under evaluation.

Treatment of underlying causes

Removing or controlling the original cause is the most consequential intervention in cirrhosis, because fibrosis that has reorganized into nodular architecture rarely regresses completely. Treatment therefore depends heavily on etiology, and the same cirrhotic endpoint can call for very different drugs.

For hepatitis C, the picture has changed the most. Direct acting antiviral (DAA) therapy is recommended for all persons with chronic HCV infection. These regimens are usually given for a few weeks to months, and a sustained virologic response is generally regarded as cure. Cure does not remove existing fibrosis, so patients with cirrhosis still require ongoing liver cancer surveillance.

Hepatitis B is handled differently. Oral nucleos(t)ide analogues such as entecavir and tenofovir suppress viral replication very effectively but seldom eliminate the virus, so treatment is generally long-term. The use of antiviral therapy to achieve long-term HBV DNA suppression leads to significant improvements in clinical outcomes, including slower progression, regression of fibrosis, and better survival. In cirrhosis specifically, the EASL guideline advises that patients with cirrhosis should be treated if HBV DNA is detectable, regardless of the level of viraemia and serum ALT. Clinicians also avoid withdrawing these drugs in cirrhosis, since patients with cirrhosis should not stop antiviral therapy, due to the risk of hepatic decompensation.

In alcohol-related liver disease, abstinence is the single most important measure, and many patients with compensated disease improve once drinking stops. Treatment of alcohol use disorder, combining psychosocial support with medication that is safe in impaired liver function, is integrated into care. In severe alcoholic hepatitis, usually defined by a Maddrey discriminant function of 32 or more, a short course of corticosteroids such as prednisolone may be given once infection has been excluded.

Metabolic disease has seen the first drugs specifically approved for MASH. Resmetirom, an oral agent that acts on the thyroid hormone receptor-β, was granted accelerated approval for adults with non-cirrhotic disease and stage F2–F3 fibrosis. A weekly GLP-1 receptor agonist, semaglutide, now carries a similar conditional authorization for the same group. Full approval requires evidence of reduced major adverse liver outcomes, which is the test these agents still have to pass. No drug is approved for MASH cirrhosis, a clear unmet need. The EASL-EASD-EASO guidance judges that in cirrhosis resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment, until further data establish liver-related benefits. Lifestyle measures remain foundational. In the semaglutide trial, average weight loss reached roughly a tenth of body weight, compared with about 2% on placebo. Diabetes also modifies the response: a meta-analysis found that in patients with type 2 diabetes, semaglutide did not improve liver fibrosis while resmetirom treatment did.

Autoimmune and cholestatic diseases follow their own logic. Autoimmune hepatitis is treated with immunosuppression, typically corticosteroids combined with azathioprine, aiming for biochemical remission and then maintenance at the lowest effective dose. Primary biliary cholangitis responds to ursodeoxycholic acid, which slows progression in most patients, while those with an inadequate response may be offered second-line agents.

Inherited metal overload is treated by removing or binding the excess metal. In hereditary hemochromatosis, regular venesection is the mainstay, and it is important to permit therapeutic phlebotomy to commence before the onset of complications. In Wilson disease, copper is managed with chelators and zinc: copper overload in Wilson's disease patients is treated with either chelating medications (D-penicillamine or trientine) or zinc salts. Zinc works by stimulating metallothionein, a protein in gut cells that binds copper and prevents its absorption. These measures do not correct the underlying metabolic defect, so they are regarded as non-curative, and liver transplantation offers the possibility of cure, but is associated with a significant morbidity and mortality. When treatment starts early and continues lifelong, both diseases typically have a favorable disease course and further development of organ-damage can be prevented, especially with respect to liver-damage.

Supportive care, nutrition and medication safety

Nutrition is the supportive measure with the clearest evidence in cirrhosis, mainly because the recommended protein intake for patients with a diagnosis of liver cirrhosis is 1.2–1.5 g/kg body weight per day. For people with sarcopenia, the AASLD clinical guidance aims higher, to 1.5 g/kg IBW/day, measured against ideal body weight. Earlier practice sometimes cut protein to limit encephalopathy, but multiple studies have shown that daily protein intake in the range of 1.2–1.5 g/kg does not increase the risk of hepatic encephalopathy and may improve nitrogen balance, muscle preservation and quality of life. Protein is therefore not restricted in encephalopathy, and the guidance is to spread intake across the day from varied sources. Early balance studies in alcohol-related disease placed the threshold for nitrogen equilibrium at about 0.8 g/kg per day, while patients were able to use intakes up to 1.8 g/kg.

Meal timing matters because the liver's storage of glycogen is reduced, so the body turns to muscle protein during long fasts. Clinicians generally aim to keep daytime gaps between eating to about three to four hours, with several small meals and an early breakfast. A late-evening snack targets the overnight fast; trials of this approach showed improvement in metabolic profile and quality of life, although muscle mass did not show consistent improvement. One recent review proposes that the snack supply roughly 50–100 g of carbohydrates, which it links to reduced overnight catabolism. Sodium restriction, used to limit ascites, is not absolute: liberalization of sodium restriction should be considered if a patient is unable to maintain nutritional targets. Deficiencies of micronutrients such as vitamin D, zinc and thiamine are common and are assessed and corrected individually.

Medication safety rests on a few well-established principles. Nonsteroidal anti-inflammatory drugs are generally avoided because they threaten kidney function, promote bleeding and blunt diuretic response. Nephrotoxic antibiotics such as aminoglycosides require careful dosing and monitoring. Sedatives, opioids and benzodiazepines can precipitate or deepen encephalopathy, so their use is minimized and dosed cautiously. Drugs cleared mainly by the liver need dose reduction as liver function declines, and analgesic use is usually limited, with acetaminophen commonly capped at a daily dose well below the usual adult maximum.

Vaccination is a central form of prevention because infection is a major trigger of decompensation. France's health authority has advised since 2007 that patients with cirrhosis be immunized against hepatitis A and B, influenza and pneumococcus. Patients with no serological markers of hepatitis B immunity should be vaccinated, and post-vaccination antibody titers should be checked. The response to vaccines weakens as disease advances: vaccine efficacy declines as liver disease progresses, so vaccines are best given early in the disease course. Cirrhosis disrupts B-cell memory and antibody production, which further blunts responses. Uptake remains low; a survey of American patients with chronic liver disease from 1999 to 2008 found that overall vaccination rates remained low at 20% for hepatitis A and 32% for hepatitis B. Pneumonia is the most frequent infection in cirrhosis and carries the highest short-term mortality, so pneumococcal vaccination is particularly important. Infection prevention also matters in hospital, where 30–50% of cirrhotics admitted to a hospital ward have sepsis, and hand hygiene, catheter care and prompt antibiotic review are standard measures.

Palliative care and advance care planning are increasingly treated as part of routine care rather than a response to the final stage. The AASLD's 2022 guidance supports early integration of palliative care for all patients with advanced liver disease, and expert opinion suggests that specialist palliative consultation be considered for all patients with decompensated cirrhosis. Importantly, transplant candidacy should not discourage specialized palliative care consultation. Advance care planning is best started in the outpatient setting early in the disease course and revisited as clinical status changes. Because hepatic encephalopathy can impair decision-making, patients are advised to name a surrogate decision-maker early. In practice, planning often lags: in one structured hepatology program, there were no advance care planning discussions in any clinic visit, and palliative consultation was linked to a higher share of patients dying at home or in hospice (70% against 12%) in that cohort.

Liver transplantation and end-stage management

Indications and candidacy

Transplantation is the only definitive treatment for decompensated cirrhosis, and organ transplantation is usually considered once complications such as ascites, variceal bleeding or encephalopathy have appeared. Clinicians weigh refractory ascites, encephalopathy, frailty and poor quality of life together with the medical severity of liver failure when deciding whether an individual should be listed Factors such as refractory ascites, hepatic encephalopathy, frailty, and poor quality of life should also be considered when considering LT for the individual patient. Hepatocellular carcinoma is an additional indication when the tumour lies within accepted transplant criteria, a question addressed in the cancer section.

Living-donor transplantation

Living-donor transplantation was developed in response to organ scarcity, and children were an early focus of the approach. Donor surgery carries real risk: estimates place donor complications at up to 20–30%, and donor death at roughly 0.1–0.5%. Donor morbidity is reported to be up to 20–30%, while donor mortality is only 0.1–0.5%. The graft's capacity to regrow makes the operation possible, since remnant tissue can expand to near-original size within about a year. Recipients of living-donor grafts appear to have survival similar to, or marginally better than, that of deceased-donor recipients, although biliary complications are more common. People who get a liver from a living donor have similar or slightly better long-term survival rates compared with those who receive a liver from a deceased donor. People who receive a liver from a living donor are more likely to have bile duct complications, which sometimes need treatment.

Allocation policy and waiting-list mortality

In the United States, allocation is driven by the Model for End-Stage Liver Disease (MELD) score. Originally devised to predict death after transjugular shunt placement, it has guided liver allocation since 2002. A sodium-inclusive version, MELD-Na, has determined priorities since 2016. Scores are truncated at 40, and ties are resolved by waiting time. Under the current system, although higher MELD-Na scores can be calculated, it is capped at 40 and waitlist priority in case of ties is then ordered by waiting time.

The score measures biological risk, but it does not capture every factor that determines whether a candidate reaches surgery. Geography, donor-recipient size matching and access to transplant centres also affect outcomes on the list. Its successor, MELD 3.0, adds patient sex and serum albumin, and it was designed to reduce the disadvantage faced by women, who have historically had lower transplant rates. The MELD 3.0 calculator includes new inputs from patient sex and serum albumin levels and has new weights for serum sodium, bilirubin, international normalized ratio, and creatinine levels. It is expected that use of MELD 3.0 scores will reduce overall waitlist mortality modestly and improve access for female liver transplant candidates. Simulation work estimated a modest reduction in deaths on the waiting list, from 7,850 under MELD-Na to 7,788 under MELD 3.0.

Outcomes after transplantation

Contemporary one-year patient survival is high, with reported figures of roughly 85% to 91%, but benefits are less clear beyond the first year. In a US cohort, five-year survival rose from 75% to 81% between eras. In a single-centre cohort followed for two decades, most late deaths were attributable to graft failure, de novo tumours and infection, and long-term survival fell to about 38% at twenty years. The overall causes of death were infection in 69 (11.6%) patients, cardiovascular complications in 58 (9.8%) patients, pulmonary complications in 8 (1.3%) patients, liver graft failure in 126 (21.2%) patients, HCC recurrence in 15 (2.6%) patients, de novo tumors in 72 (12.1%) patients, and miscellaneous in 40 (6.7%) patients.

Recurrence of the original disease is a major concern. Recurrent hepatitis C is now the commonest cause of graft failure and retransplantation in infected recipients, and it lowers survival relative to other indications. The development of decompensated cirrhosis due to recurrent hepatitis C is now the most frequent cause of graft failure, patient death, and the need for retransplantation in HCV-infected recipients. Fibrosis can also progress faster in a transplanted liver than in a native one, with one estimate of about 0.4 stages per year. Once decompensation occurs in graft cirrhosis, mortality is substantial; in one cohort, death followed in 18% of patients after the first overt episode. Lifelong immunosuppression is required to prevent rejection, and these agents carry their own toxicity, which includes infection risk and metabolic and renal effects.

Patients who are not transplant candidates

Patients who are ineligible for transplantation, whether because of comorbidity, frailty or uncontrolled extrahepatic disease, are managed with symptom-directed therapy and disease-specific procedures. Transjugular shunts may palliate portal hypertension in selected cases, and the mortality risk after such shunting is the reason MELD was first developed. Palliative care, which focuses on symptom control, prognostic communication and advance care planning, becomes central when the balance of benefit and burden no longer favours transplantation or further intervention. Palliative care should therefore be introduced early, rather than only at the terminal stage, for patients with end-stage disease who are not listed.

Antifibrotic and investigational therapies

Antifibrotic drug development in cirrhosis is aimed at the cells and signals that produce scar tissue, rather than only at the underlying cause. Activated hepatic stellate cells are the main effector cells in liver fibrosis, and much of the current preclinical work targets them, either by blocking their activation, by reducing profibrogenic signaling, or by promoting their clearance. Profibrogenic pathways such as those driven by transforming growth factor β and platelet-derived growth factor receptors are also under study. Metabolic receptors form a second group of targets, largely in metabolic dysfunction-associated steatohepatitis (MASH), where fibrosis is the main determinant of long-term outcome. Several candidates are in clinical trials. Belapectin, a galectin-directed agent, has been tested in patients with advanced fibrosis or cirrhosis from MASH and has received FDA Fast Track designation. Efruxifermin, a fibroblast growth factor 21 analogue, showed no fibrosis regression at 36 weeks in a phase 2b trial in compensated MASH cirrhosis but showed improvement at 96 weeks. Fazirsiran, which lowers the production of the abnormal Z-variant alpha-1 antitrypsin protein, is being studied for liver scarring in alpha-1 antitrypsin deficiency over about two years. No antifibrotic drug has yet been approved specifically for liver fibrosis.

Cell-based approaches have also been tested. Although mesenchymal stromal cell transplantation showed antifibrotic effects in several early studies, a UK multicentre randomized phase 2 trial found no significant improvement in fibrosis or liver function, which keeps the approach controversial.

Disease-modifying agents already in clinical use for other indications have been evaluated in cirrhosis, with mixed results. Statins are the most studied. Simvastatin lowers portal pressure, and a 2016 randomized trial in patients recovering from variceal bleeding reported improved survival, but the 2018 clinical guidelines did not recommend statins in routine practice because only one positive trial had survival endpoints. A large trial of simvastatin 40 mg/day reported a significant mortality reduction but also an unexpectedly high rate of rhabdomyolysis. The phase 3 LIVERHOPE trial, which enrolled 237 patients with decompensated cirrhosis, mostly alcohol-related, and treated them with simvastatin 20 mg/day plus rifaximin 1200 mg/day for 12 months, did not reduce acute-on-chronic liver failure, transplantation or death. The StatLiver trial of atorvastatin in patients with clinically significant portal hypertension likewise did not reduce mortality or hospital admissions. Rifaximin, a poorly absorbed antibiotic, has shown benefit against recurrent hepatic encephalopathy, but a French trial found no survival or spontaneous bacterial peritonitis benefit in decompensated patients with low-protein ascites.

Trial design raises its own difficulties. Historically, improvement of fibrosis by at least one stage without worsening of steatohepatitis, and resolution of steatohepatitis, were accepted as surrogate endpoints for accelerated approval. However, liver biopsy is invasive and is rarely used to monitor treatment response in routine practice, and among histological endpoints only fibrosis has been shown to predict long-term outcome independently. Noninvasive tests, including elastography and serum fibrosis indices, are mostly surrogates of fibrosis, and trials are increasingly using them for enrollment and monitoring. Histological or surrogate change, however, must be linked to reductions in liver-related mortality, hepatocellular carcinoma and portal hypertensive complications, which requires extended follow-up. Because decompensation prevention is more clinically relevant than histological regression in advanced disease, but harder to demonstrate within current trial designs, the time needed to show a survival benefit remains a central constraint.

Several uncertainties remain unresolved. The durability of fibrosis improvement after treatment stops, and whether it translates into lasting reduction in clinical events, has not been established. Safety is a particular concern in decompensated patients, who were underrepresented or excluded from many early trials and in whom drug-related harm, such as the muscle toxicity seen with high-dose statins, may be more consequential. The cost of long-term therapy and of the monitoring needed to evaluate it is also a practical constraint on whether any candidate agent could be adopted widely.

Epidemiology and disease burden

Estimates of how many people live with cirrhosis have shifted as survey methods have improved. A population-based analysis of NHANES data for 1999 to 2004 put the national prevalence at about 0.27%, or 633,323 adults, and it reported that previous best-guess estimates pegged the number of adults with cirrhosis at about 400,000. Most of these people were unaware of the diagnosis; 69 percent reported that they were unaware of having liver disease. Later work has pushed the figures higher. An analysis of insured adults from 2012 to 2018 found that prevalence roughly doubled, from 0.34% to 0.71%. A 2017–2020 NHANES analysis, which used a different case definition, reported a prevalence of cirrhosis in the United States of 2.6%. Across the US population studies reviewed in the insured-adult report, estimates fluctuat[e] from 0.27%-1.06%, so the figure depends heavily on how cases are identified.

Men and older adults carry the greatest share of the disease. In the NHANES cohort, diabetes, alcohol abuse, hepatitis C and B, male sex, and older age were all independently associated with cirrhosis. The insured-adult population had a mean age of 62.2 years, and 225,089 (60.6%) of the patients were ≥60 years old. Mortality follows the same pattern. Globally, the death rate among men was estimated to be 1.51 times higher than that among females in 2019, and mortality rises with age.

The global burden is large. In 2019, cirrhosis was associated with 2.4% of global deaths, and a GBD 2019 analysis counted 1.47 million deaths due to cirrhosis that year. Total deaths have kept rising in step with population growth, but age-standardized mortality has fallen. Between 1990 and 2017, the age standardized rate decreased from 21.0 per 100,000 population to 16.5 per 100,000, and the rate was markedly uneven across regions: Sub-Saharan Africa had the highest ASR (32.2 deaths per 100,000), while high-income areas had the lowest (10.1 deaths per 100,000). In the United States, the disease ranks as the 12th leading cause of death overall and the fifth leading cause of death for patients aged 45 to 54.

The leading causes have changed over time. Globally, the cause mix is shaped by two opposing trends: the rising prevalence of obesity and increased alcohol consumption on the one hand, and improvements in the management of hepatitis B virus and hepatitis C virus infections on the other. Within the GBD 2017 data, the age-standardized mortality from hepatitis C, alcohol-related and NASH-related cirrhosis all increased over the study period, with NASH showing the steepest rise. In the insured US cohort, the most frequent etiologies were alcohol-related (26.0%), NASH (20.9%) and HCV (20.0%), and the increase between 2012 and 2018 was driven mainly by NASH (3.9-fold) and alcohol-related (2-fold) cirrhosis. Regional differences are also marked. In the US, prevalence rose in every state, with Southern states having the most rapid rise (2.3-fold), and earlier NHANES data showed that the prevalence was higher in non-Hispanic blacks and Mexican Americans, those living below the poverty level, and those with less than a 12th grade education.

The economic burden is substantial and rising. Using National Readmissions Database data, one analysis reported that from 2001 to 2011, the annual cost of cirrhosis-related hospitalizations doubled from $4.8 billion to $9.8 billion. A separate study found that the hospitalization costs for patients with cirrhosis increased 30.2% from 2008 to 2014 to $7.37 billion. Total spending is larger still once outpatient and drug costs are included: a national estimate based on 2016 expenditure put the national cost of cirrhosis-related care at $32.5 billion. At the patient level, a national insurance study estimated the annualized cost for cirrhosis per patient was $36,384 (inpatient medical $15,009, emergency: $1051, and pharmaceutical: $8917). Costs are concentrated in advanced disease, with the monthly cost of care for decompensated cirrhosis was $3969.30, and readmissions add to the burden, since the costs for individual patients readmitted at 30 days are substantially higher ($73,252) than those readmitted after 30 days ($62,053) or those not readmitted ($5719).

Prevention and public health

Most cirrhosis traces back to a small number of causes that can be prevented or controlled, so public health work focuses on those causes. Hepatitis B vaccination is the clearest example. The HBV vaccine is highly effective at preventing vertical transmission when the full three or four dose schedule is given at birth and in early infancy, which in turn prevents onward transmission, cirrhosis and HCC. Taiwan's universal infant program, introduced from 1984, provides the longest real-world record. Its vaccinated birth cohorts show an age- and sex-adjusted rate ratio of 0.20 for hepatocellular carcinoma incidence and 0.11 for chronic liver disease mortality, and a long randomized trial reported 70% protective efficacy against liver cancer deaths. Coverage remains uneven, however: global coverage of the birth dose was only 42%.

Prevention among adults relies on reducing blood-borne transmission. Hepatitis C in particular spreads mainly through shared injecting equipment, and WHO's strategy lists people who inject drugs, men who have sex with men and prisoners as key populations for prevention and testing. Harm reduction measures such as sterile injecting equipment programs and opioid agonist treatment are the main tools for this group, and the same logic applies to safe injection practices in health care settings. Preventing new hepatitis C infection is as important as curing existing infections, because each new infection carries a future risk of cirrhosis.

Population-level alcohol policy addresses the largest non-viral cause. Taxation and minimum unit pricing (MUP) are the most studied measures. In Scotland, where a floor price of £0.50 per unit was introduced in May 2018, deaths wholly attributable to alcohol consumption fell by 13.4%, and deaths due to alcoholic liver disease also declined significantly (−11.7%). Tax evidence points the same way: a decrease in taxation has been followed by a dramatic increase in liver cirrhosis mortality, while tax increases reduce cirrhosis mortality rates in the long term. The effects are not uniform, and the size of the effect varies across countries. Minimum pricing and taxation also work differently: MUP sets a legal minimum price, whereas taxes can be partly offset by changes in retailers' pricing. A rapid review found that minimum pricing reduces consumption among people who drink heavily and those in lower socio-economic groups, which is where most of the cirrhosis burden is concentrated.

Secondary prevention aims to find fibrosis before decompensation occurs. Screening is usually targeted at people with chronic viral hepatitis, heavy alcohol use or metabolic risk factors. Where prevalence is high, guidance can extend screening to the general population, either universally or by targeting specific birth cohorts, depending on local epidemiology. Noninvasive tools such as elastography and serum fibrosis scores make it practical to screen in primary care without routinely performing biopsy, which is important because most patients with early disease have no symptoms.

At the global level, WHO's 2016 strategy defined elimination of viral hepatitis as a public health threat by 2030 as a 90% reduction in incidence and a 65% reduction in mortality compared to 2015, and its targets also call for diagnosis of at least 90% of infected individuals and treatment of at least 80% of those diagnosed. Progress is real but incomplete. WHO's 2026 report noted that viral hepatitis B and C, the two infections responsible for 95% of hepatitis-related deaths, claimed 1.34 million lives in 2024, and that current rates of progress are insufficient to meet all 2030 elimination targets. WHO projects that without sustained action, viral hepatitis would cause an additional 9.5 million new infections, 2.1 million liver cancer cases, and 2.8 million deaths by 2030.

Health system barriers explain much of the gap between these targets and outcomes. Around 304 million people worldwide live with hepatitis B or C, and for most, testing and treatment remain beyond reach. Because cirrhosis is silent for years, patients often reach care only after a complication appears. Reducing the burden therefore requires linking screening to antiviral treatment, surveillance for liver cancer and specialist referral, and this requires coordinated primary and specialist services. WHO's director-general has argued that elimination is achievable with sustained political commitment, backed by reliable domestic financing.

History of the concept and research

Laennec, better remembered today for inventing the stethoscope, borrowed a Greek adjective meaning "tawny" to name the disease in 1819, a choice that reflected the yellowish-brown colour of nodular livers René Laennec (1781–1826) was the first person to use the term cirrhosis (meaning tawny or brownish yellow, but not simply yellow) in a brief footnote to his 1819 treatise about auscultation. The lesion itself was older than the word. A description of cirrhosis had been published previously by John Browne (1642-1702), a seventeenth century English surgeon and anatomist. Matthew Baillie (1762-1823), an anatomist and physician at St George's Hospital in London, and a correspondent with Laennec had made the link between alcohol and cirrhosis but Laennec seems to have been unaware of this. Laennec's own unpublished treatise of 1804–1808 elaborated what is now called the micronodular form, but he did not speculate on the cause of the condition. Furthermore, he erroneously included a few other entities such as cystic disease of the liver within the spectrum of cirrhosis.

The eponym "Laennec's cirrhosis" spread unevenly. A survey of nineteenth-century literature found that it entered common use only after William Osler's textbook appeared, and it has remained uncommon in France, where the term is rarely used with his name attached the eponym "Laennec's cirrhosis" is rarely used in France.

Twentieth-century clinical work turned the descriptive term into a tool for prognosis. Child and Turcotte proposed their grading in 1964 to predict death after portocaval shunt surgery, a procedure used in patients with portal hypertension as a predictor of postoperative (portocaval shunt surgery) mortality. Pugh and colleagues revised it in 1973, in a study whose focus was operative mortality in patients with bleeding esophageal varices. Pugh's revision traded the nutrition-based item for the clotting test, and the resulting Child-Pugh system became the standard for decades. Accounts differ on the details: one source notes that Pugh later proposed using the presence and severity of hepatic encephalopathy as an alternative to general condition. Over the same decades, research separated viral hepatitis from alcohol-related injury; hepatitis B surface antigen was identified in 1965 and hepatitis C virus was cloned in 1989.

The MELD score was a later product of the 2000s. Malinchoc et al. used a Cox proportional-hazards regression model to identify four variables (serum bilirubin, serum creatinine, international normalized ratio (INR) for prothrombin time, and the cause of the underlying liver disease) in patients undergoing elective TIPS, and the score was first called the Mayo model. A 2001 validation study tested it in a broader population of disease severity and etiology. The etiology turned out to be relatively unimportant, and was also regarded as relatively subjective; it was therefore removed from the score. In the United States, in February 2002, the allocation system for liver transplantation switched from being based on CTP classification to the MELD score. Later refinements followed. Adding serum sodium (MELD-Na) increased the accuracy of the score in predicting waiting list mortality, and the MELD 3.0 calculator includes new inputs from patient sex and serum albumin levels and has new weights for serum sodium, bilirubin, international normalized ratio, and creatinine levels.

Diagnosis changed in parallel. Liver biopsy was the reference standard for staging fibrosis for most of the century, but its invasiveness and sampling error limited repeated assessment. In the early to mid 2000s, transient elastography measuring liver stiffness by ultrasound and serum panels such as APRI and FIB-4 were introduced, allowing clinicians to screen for advanced fibrosis without biopsy. The treatment of hepatitis C was transformed more abruptly. Interferon-based regimens often produced modest cure rates and poor tolerance, whereas direct-acting antivirals approved from 2013 onward achieved sustained virological response in most treated patients, including many with cirrhosis. This made cure of the underlying infection, and in some cases regression of fibrosis, a realistic outcome.

Nomenclature has continued to shift. Fatty liver conditions formerly labelled NAFLD and NASH were renamed in 2023 as MASLD and MASH, placing metabolic dysfunction at the centre of the diagnosis. Staging has also been refined: the Baveno VII consensus of 2022 introduced compensated advanced chronic liver disease as a category that precedes decompensation. The question of reversibility remains unsettled. Histological regression has been documented after the cause is removed, but established nodular cirrhosis rarely returns to normal architecture, and studies differ on whether regression should be judged by biopsy, elastography or clinical outcome.

References

1. Fibrosis and hepatic regeneration mechanism - PMC - NIHpmc.ncbi.nlm.nih.gov
2. Cirrhosis - Hepatology - Merck Manual Professional Editionmerckmanuals.com
3. Gross pathology of cirrhotic liverpressbooks.bccampus.ca
4. Hepatic venous pressure gradient: clinical use in chronic liver diseasee-cmh.org
5. Cirrhosis - Liver & intrahepatic bile ductspathologyoutlines.com
6. Hepatic Cirrhosis - StatPearls - NCBI Bookshelf - NIHncbi.nlm.nih.gov
7. A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosisclinicaltrials.gov
8. Compositions and methods directed to treating liver fibrosisimage-ppubs.uspto.gov
9. Liver Cirrhosis - an overviewsciencedirect.com
10. Portal Venous Pressure - an overviewsciencedirect.com
11. Portal Hypertension—Noninvasive Multiparametric Ultrasound-Based Criteria and Measurementsmednexus.org
12. Cirrhosis - an overviewsciencedirect.com
13. Changes in the etiology of liver cirrhosis and the corresponding management strategies - PMCpmc.ncbi.nlm.nih.gov
14. Liver diseases: epidemiology, causes, trends and predictionsnature.com
15. Update on the Complications and Management of Liver Cirrhosis - PMCpmc.ncbi.nlm.nih.gov
16. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC - Clinical Gastroenterology and Hepatologycghjournal.org
17. Alcohol consumption and the risk of developing liver cirrhosis: Implications for future research - ScienceDirectsciencedirect.com
18. Influence of sex in alcohol‐related liver disease: Pre‐clinical and clinical settings - Bizzaro - 2023 - United European Gastroenterology Journal - Wiley Online Libraryonlinelibrary.wiley.com
19. Sex Differences in Alcohol Consumption and Alcohol-Associated Liver Disease - Mayo Clinic Proceedingsmayoclinicproceedings.org
20. Female Sex and the Risk of Liver Cirrhosis: Scandinavian Journal of Gastroenterology: Vol 32, No 11tandfonline.com
21. Nomenclature Change from NASH/NAFLD to MASH/MASLDlabcorp.com
22. The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography - PMCpmc.ncbi.nlm.nih.gov
23. MASLD Now the Leading Cause of Cirrhosis Among US Veterans - Gastroenterology Advisorgastroenterologyadvisor.com
24. Full article: MASLD and MASH: how a change of nomenclature may impact our approach in treating liver diseasetandfonline.com
25. MASLD: Leading Cause of Cirrhosis in South America? - EMJemjreviews.com
26. New MASLD Nomenclatureaasld.org
27. MetALD: decoding the evolution of steatotic liver disease nomenclature and implications for clinical practice and beyondncbi.nlm.nih.gov
28. CXCL6‐EGFR‐induced Kupffer cells secrete TGF‐β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C‐MYC/EZH2 pathway in liver fibrosisncbi.nlm.nih.gov
29. Activation of TGF-β1-CD147 positive feedback loop in hepatic stellate cells promotes liver fibrosisnature.com
30. Liver cirrhosis - ScienceDirectsciencedirect.com
31. Cirrhosis - Knowledge @ AMBOSSamboss.com
32. Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insightslink.springer.com
33. The Role of Vascular Injury and Congestion in the Pathogenesis of Cirrhosis: the Congestive Escalator and the Parenchymal Extinction Sequencelink.springer.com
34. TGF-β inhibitors: the future for prevention and treatment of liver fibrosis?ncbi.nlm.nih.gov
35. TGF‐β signalling and liver disease - Fabregat - 2016 - The FEBS Journal - Wiley Online Libraryfebs.onlinelibrary.wiley.com
36. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019ncbi.nlm.nih.gov
37. Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)cdn.clinicaltrials.gov
38. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies - Journal of Hepatologyjournal-of-hepatology.eu
39. Core Concepts - Evaluation and Prognosis of Persons with Cirrhosis - Evaluation, Staging, and Monitoring of Chronic Hepatitis C - Hepatitis C Onlinehepatitisc.uw.edu
40. Compensated liver cirrhosis: Natural course and disease-modifying strategieswjgnet.com
41. Acute-on-chronic liver failure - PMC - NIHpmc.ncbi.nlm.nih.gov
42. EASL Clinical Practice Guidelines on acute-on-chronic liver failure - ScienceDirectsciencedirect.com
43. Acute-on-chronic liver failure: from definitions to management - Kadayifci - Annals of Palliative Medicineapm.amegroups.org
44. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regressionncbi.nlm.nih.gov
45. Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review - PMCpmc.ncbi.nlm.nih.gov
46. Regression of portal hypertension: underlying mechanisms and therapeutic strategieslink.springer.com
47. A review of liver fibrosis and cirrhosis regressionjpatholtm.org
48. Reversibility of liver fibrosiselsevier.es
49. Evaluation and Prognosis of Persons with Cirrhosishepatitisc.uw.edu
50. Clinical outcomes of compensated and decompensated cirrhosis: A long term studywjgnet.com
51. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis - Journal of Hepatologyjournal-of-hepatology.eu
52. Editorial: Acute-On-Chronic Liver Failure: Natural History, Mechanism, and Treatmentncbi.nlm.nih.gov
53. Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectivesmdpi.com
54. Liver Cirrhosis Symptoms and Treatmenthospital.uillinois.edu
55. Cirrhosis - Symptoms and causes - Mayo Clinicmayoclinic.org
56. Cirrhosis of the Liver: What It Is, Symptom & Treatmentmy.clevelandclinic.org
57. Cirrhosis: MedlinePlus Medical Encyclopediamedlineplus.gov
58. Diagnosis of Cirrhosis - NIDDKniddk.nih.gov
59. Commonly encountered symptoms and their management in patients with cirrhosisncbi.nlm.nih.gov
60. Frontiersfrontiersin.org
61. Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomesjournals.plos.org
62. The Care of the Decompensated Cirrhotic Patient - ScienceDirectsciencedirect.com
63. Risk of injuries before and after a diagnosis of cirrhosis: A population-based cohort studyncbi.nlm.nih.gov
64. Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomesncbi.nlm.nih.gov
65. The Clinical Courses and Prognosis of Cirrhotic Patients after First Acute Decompensation: Prospective Cohort Studyncbi.nlm.nih.gov
66. Cirrhosisyalemedicine.org
67. Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes - PMCpmc.ncbi.nlm.nih.gov
68. Commonly encountered symptoms and their management in patients with cirrhosis - PubMedpubmed.ncbi.nlm.nih.gov
69. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
70. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosiswjgnet.com
71. Physiopathology of splanchnic vasodilation in portal hypertensionwjgnet.com
72. Asymmetric Sensitivity of Hepatic Venous Pressure Gradient to Portal and Sinusoidal Resistance: An In Vitro Experimental Study - PMCpmc.ncbi.nlm.nih.gov
73. Portal hypertension and hepatocellular carcinoma: Navigating uncharted watersncbi.nlm.nih.gov
74. Portal Hypertension: Background, Etiology, Pathophysiologyemedicine.medscape.com
75. Hypersplenismaccessmedicine.mhmedical.com
76. Hypersplenism • The Blood Projectthebloodproject.com
77. Splenomegaly Workup: Approach Considerations, Findings in Hypersplenism, Splenectomy and Splenic Biopsyemedicine.medscape.com
78. Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antiviralsncbi.nlm.nih.gov
79. Portal Hypertension among Patients with Chronic Liver Disease Admitted to the Department of Internal Medicine of a Tertiary Care Centrencbi.nlm.nih.gov
80. Portal Hypertension - an overviewsciencedirect.com
81. 1 Pathophysiology of portal hypertension - ScienceDirectsciencedirect.com
82. Diagnosis, Evaluation, and Management of Ascites,... : Hepatologyjournals.lww.com
83. Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndromeccjm.org
84. Diagnosis and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndromeconsultqd.clevelandclinic.org
85. Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation? - Clinical Gastroenterology and Hepatologycghjournal.org
86. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis - Journal of Hepatologyjournal-of-hepatology.eu
87. Management of Refractory Ascites in Cirrhosisaasld.org
88. Refractory Ascites in Patients With Cirrhosis - PMC - NIHpmc.ncbi.nlm.nih.gov
89. Terlipressin for hepatorenal syndrome: The practical choice for cliniciansjournals.lww.com
90. Terlipressin versus other vasoactive drugs for hepatorenal syndrome - PMCpmc.ncbi.nlm.nih.gov
91. From Past to Present to Future: Terlipressin and Hepatorenal Syndrome-Acute Kidney Injury - PMCpmc.ncbi.nlm.nih.gov
92. Early Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers Cost - PMCpmc.ncbi.nlm.nih.gov
93. Evaluation and management of patients with refractory asciteswjgnet.com
94. Hepatic Encephalopathy following Transjugular Intrahepatic Portosystemic Shunt Placement - PMCpmc.ncbi.nlm.nih.gov
95. Pathogenesis of Hepatic Encephalopathy - Ciećko-Michalska - 2012 - Gastroenterology Research and Practice - Wiley Online Libraryonlinelibrary.wiley.com
96. Hyperammonemia and Systemic Inflammatory Response Syndrome Predicts Presence of Hepatic Encephalopathy in Dogs with Congenital Portosystemic Shuntsncbi.nlm.nih.gov
97. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy - Journal of Hepatologyjournal-of-hepatology.eu
98. Precipitating Factors and Treatment Outcomes of Hepatic Encephalopathy in Liver Cirrhosisncbi.nlm.nih.gov
99. Why do we use Lactulose and Rifaximin for Hepatic Encephalopathy?aasld.org
100. Covert Hepatic Encephalopathy: Not as Minimal as You Might Thinkcghjournal.org
101. Hepatic Encephalopathy: Symptoms, Causes, Grading & Treatmentmy.clevelandclinic.org
102. Hepatic Encephalopathy Workup: Approach Considerations, Laboratory Studies, Imaging Studiesemedicine.medscape.com
103. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidenceovid.com
104. Rifaximin reduces risk for overt hepatic encephalopathy recurrence by 60% vs. lactulosehealio.com
105. Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis - PMCpmc.ncbi.nlm.nih.gov
106. Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximinncbi.nlm.nih.gov
107. Hepatic encephalopathy as a result of ammonia-induced increase in GABAergic tone with secondary reduced brain energy metabolismncbi.nlm.nih.gov
108. Pathogenesis of Hepatic Encephalopathy: Role of Ammonia and Systemic Inflammation - ScienceDirectsciencedirect.com
109. Hepatic Encephalopathy: Etiology, Pathogenesis, and ...vetfolio-vetstreet.s3.amazonaws.com
110. Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy - ScienceDirectsciencedirect.com
111. Management of Variceal Hemorrhagencbi.nlm.nih.gov
112. Wale marken.wikipedia.org
113. The Baveno VI criteria for predicting esophageal varicesscielo.isciii.es
114. Management of acute variceal bleeding: updated APASL guidelineslink.springer.com
115. UK guidelines on the management of variceal haemorrhage in cirrhotic patients - PMCpmc.ncbi.nlm.nih.gov
116. ACG & AASLD Joint Clinical Guideline: Prevention and Management ofacgcdn.gi.org
117. Management of Refractory Variceal Bleed in Cirrhosis - PMCpmc.ncbi.nlm.nih.gov
118. Guidelines for the Management of Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertensionxiahepublishing.com
119. Management of Variceal Hemorrhage - PMC - NIHpmc.ncbi.nlm.nih.gov
120. Early Use of TIPSS in Patients With Cirrhosis and Variceal Bleedingclinicaltrials.gov
121. Diagnostic accuracy of serological and imaging tests used in surveillance for hepatocellular carcinoma in adults with cirrhosis: a systematic review protocolncbi.nlm.nih.gov
122. Diagnostic accuracy of ultrasound and alpha-fetoprotein measurement for hepatocellular carcinoma surveillance: a retrospective comparative studylink.springer.com
123. Risk-stratified surveillance for hepatocellular carcinoma - PMCpmc.ncbi.nlm.nih.gov
124. Surveillance of hepatocellular carcinoma in cirrhotic patients: Current knowledge and future directions - PubMedpubmed.ncbi.nlm.nih.gov
125. Abdominal ultrasound and alpha‐fetoprotein for the diagnosis of hepatocellular carcinoma - PMCpmc.ncbi.nlm.nih.gov
126. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis - Gastroenterologygastrojournal.org
127. Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: A retrospective cohort studyncbi.nlm.nih.gov
128. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update - PMCpmc.ncbi.nlm.nih.gov
129. Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey - PMCpmc.ncbi.nlm.nih.gov
130. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinomancbi.nlm.nih.gov
131. Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With Human Immunodeficiency Virus - PMCpmc.ncbi.nlm.nih.gov
132. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysislink.springer.com
133. Management of hepatocellular carcinoma: An updatencbi.nlm.nih.gov
134. Risk of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C virus infection in people with HIVacademic.oup.com
135. Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antiviralsncbi.nlm.nih.gov
136. Hepatopulmonary syndrome: pathophysiological mechanisms and clinical implicationsncbi.nlm.nih.gov
137. THE HEPATOPULMONARY SYNDROMEncbi.nlm.nih.gov
138. Hepatopulmonary syndrome and portopulmonary hypertension: what's new? - PubMedpubmed.ncbi.nlm.nih.gov
139. Disruption of Hepatic Sinusoidal Homeostasis Leads to Hepatopulmonary Syndromencbi.nlm.nih.gov
140. Portopulmonary Hypertension and Hepatopulmonary Syndrome: Is Transplant Always the Answer?link.springer.com
141. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment - Raevens - 2015 - Liver International - Wiley Online Libraryonlinelibrary.wiley.com
142. Cirrhotic Cardiomyopathy - an overviewsciencedirect.com
143. Cirrhotic cardiomyopathy: Pathogenesis, clinical features, diagnosis, treatment and prognosis - ScienceDirectsciencedirect.com
144. Diagnostic Criteria of Cirrhotic Cardiomyopathy: Out With the Old, in With the New? - Liu - 2021 - Hepatology - Wiley Online Libraryonlinelibrary.wiley.com
145. Cirrhotic Cardiomyopathyjacc.org
146. Current management strategies for sarcopenia and frailty in cirrhosis: Missing link in transplant candidacy - PubMedpubmed.ncbi.nlm.nih.gov
147. Current management strategies for sarcopenia and frailty in cirrhosis: Missing link in transplant candidacy - PMCpmc.ncbi.nlm.nih.gov
148. Pulmonary vascular complications of cirrhosis: hepatopulmonary syndrome and portopulmonary hypertension - PubMedpubmed.ncbi.nlm.nih.gov
149. New updates on hepatopulmonary syndrome: A comprehensive review - ScienceDirectsciencedirect.com
150. Portopulmonary hypertension: A focused review for the internistccjm.org
151. Cirrhotic Cardiomyopathy - StatPearls - NCBI Bookshelf - NIHncbi.nlm.nih.gov
152. Diagnostic and defining criteria of CCM CCM: Cirrhotic cardiomyopathy,...researchgate.net
153. Sarcopenia in cirrhosis: a clinical practice review - Ghumman - Annals of Palliative Medicineapm.amegroups.org
154. Cirrhosis: Diagnosis and Managementaafp.org
155. Physicians over-relying on a commonly used laboratory test can miss liver cirrhosisweb.musc.edu
156. Early Detection of Liver Cirrhosis: Tests and Screeningcontinentalhospitals.com
157. Cirrhosis: Overview, Epidemiology, Diagnosis of Cirrhosis: Introductionemedicine.medscape.com
158. Is FIB-4 the right tool for screening for liver fibrosis? - ScienceDirectsciencedirect.com
159. Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patientsncbi.nlm.nih.gov
160. Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C—An Experience from a Tertiary Care Hospital - PMCpmc.ncbi.nlm.nih.gov
161. Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluationaafp.org
162. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsyacademic.oup.com
163. Liver Imaging - StatPearls - NCBI Bookshelf - NIHncbi.nlm.nih.gov
164. State-of-the-art imaging of liver fibrosis and cirrhosis: A comprehensive review of current applications and future perspectives - ScienceDirectsciencedirect.com
165. Diagnostic tests - Cirrhosis in Over 16s - NCBI Bookshelf - NIHncbi.nlm.nih.gov
166. Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine resultsncbi.nlm.nih.gov
167. What Is a Child-Pugh Score?my.clevelandclinic.org
168. Child-Pugh Score - an overviewsciencedirect.com
169. Child-Pugh Score for Chronic Liver Disease and Cirrhosishealthline.com
170. Calcolatore Child-Pugh — Calcola il Punteggio Cirrosi Epaticasismed-it.com
171. Proposing a Sex-Adjusted Sodium-Adjusted MELD Score for Liver Transplant Allocationncbi.nlm.nih.gov
172. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease–Sodium Scores on Patient Outcomes - Gastroenterologygastrojournal.org
173. The MELD score in patients awaiting liver transplant: Strengths and weaknesses - ScienceDirectsciencedirect.com
174. GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort studyncbi.nlm.nih.gov
175. Proposing a Sex-Adjusted Sodium-Adjusted MELD Score for Liver Transplant Allocationjamanetwork.com
176. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteriancbi.nlm.nih.gov
177. Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort studyncbi.nlm.nih.gov
178. The Baveno VII concept of cirrhosis recompensation - ScienceDirectsciencedirect.com
179. Validation and expansion of Baveno VII recompensation criteriajournal-of-hepatology.eu
180. Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease - PubMedpubmed.ncbi.nlm.nih.gov
181. Use Of The Child Pugh Score In Liver Disease - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
182. IMPACT OF MELD SODIUM ON LIVER TRANSPLANTATION WAITING LISTncbi.nlm.nih.gov
183. The Baveno VII concept of cirrhosis recompensation - PubMedpubmed.ncbi.nlm.nih.gov
184. 2925 AASLD/IDSA Chronic Hepatitis B Guidelines - Guideline Summary - Guideline Centralguidelinecentral.com
185. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection - ScienceDirectsciencedirect.com
186. Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure - Gastroenterologygastrojournal.org
187. MASH and liver fibrosis: Clinical trials to watch - ScienceDirectsciencedirect.com
188. EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy - Journal of Hepatologyjournal-of-hepatology.eu
189. Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials - ScienceDirectsciencedirect.com
190. Wilson's disease and hemochromatosis - PubMedpubmed.ncbi.nlm.nih.gov
191. [Hereditary Liver Diseases: Wilson's Disease and Hemochromatosis] - PubMedpubmed.ncbi.nlm.nih.gov
192. Wilson's disease gene therapyimage-ppubs.uspto.gov
193. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection - Journal of Hepatologyjournal-of-hepatology.eu
194. Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspectiveexplorationpub.com
195. Therapeutic Mechanisms of Resmetirom and Semaglutide in MASLD/MASH: A Review of Inflammatory and Fibrotic Metabolites - PMCpmc.ncbi.nlm.nih.gov
196. FDA Approves Semaglutide for MASH With Fibrosisajmc.com
197. EASL Clinical Practice Guidelines on nutrition in chronic liver disease - Journal of Hepatologyjournal-of-hepatology.eu
198. Malnutrition in the Adult with Cirrhosisaasld.org
199. Nutritional interventions in liver cirrhosis: dietary management for improved outcomeslink.springer.com
200. [Vaccination in patients with cirrhosis] - PubMedpubmed.ncbi.nlm.nih.gov
201. Vaccination in Chronic Liver Disease: An Update - ScienceDirectsciencedirect.com
202. Hepatitis B, Hepatitis A, and Pneumococcal Immunization Status in Patients with Cirrhosis of the Liverovid.com
203. Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021clinicaltrials.gov
204. Palliative care and Advanced Liver Diseaseaasld.org
205. When is the Optimal Time to Refer Patients with End-Stage Liver Disease to Palliative Care Specialists?mypcnow.org
206. Advance Care Planning for Patients With Cirrhosisonlinelibrary.wiley.com
207. Advance Care Planning for Patients with Cirrhosis in a Structured Inpatient/Outpatient Hepatology Program - PubMedpubmed.ncbi.nlm.nih.gov
208. Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiotancbi.nlm.nih.gov
209. The survival benefit of deceased donor liver transplantation using MELD 3.0: A contemporary analysis - PMCpmc.ncbi.nlm.nih.gov
210. Donor’s ability to comprehend and carefully assess the benefits and risks of donation in living donor liver transplantation: a Pakistani perspective – a short communicationncbi.nlm.nih.gov
211. Living-donor liver transplantmymlc.com
212. Mortality in End Stage Liver Patients Above MELD 3.0 of 40 - PMCpmc.ncbi.nlm.nih.gov
213. MELD 3.0 in Advanced Chronic Liver Diseaseannualreviews.org
214. Long‐Term Outcomes of Liver Transplant Recipients. What Do Patients Die From?onlinelibrary.wiley.com
215. Liver Transplantation and Hepatitis Cncbi.nlm.nih.gov
216. Improving Liver Allocation: MELD, PELD, Status 1A and Status 1Bhrsa.gov
217. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era - Gastroenterologygastrojournal.org
218. Survival Outcomes of Liver Transplantation Amid Rising Recipient and Donor Risk Profiles - PMCpmc.ncbi.nlm.nih.gov
219. Screening and care of patients with graft cirrhosis following liver transplantation - PMCpmc.ncbi.nlm.nih.gov
220. Living liver donor: Risks, results, and what to expectmedicalnewstoday.com
221. Guide to Living Donor Liver Transplantationcolumbiasurgery.org
222. Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trialjamanetwork.com
223. Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial - PMCpmc.ncbi.nlm.nih.gov
224. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Gastroenterology & Hepatologythelancet.com
225. Statin-Antibiotic Combo Fails in Decompensated Cirrhosismedscape.com
226. Simvastatin and rifaximin in patients with decompensated cirrhosis: Still a place for LIVER HOPE? - Journal of Hepatologyjournal-of-hepatology.eu
227. From mechanisms to anti-fibrotic drugs in hepatic stellate cell research: a global bibliometric analysis with patent and clinical perspectives (2000–2025)ncbi.nlm.nih.gov
228. Antifibrotic therapies for metabolic dysfunction-associated ...jhep-reports.eu
229. Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicinelink.springer.com
230. MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MDajmc.com
231. Rethinking MASH clinical endpoints: Is liver fibrosis the key predictor of adverse outcomes? - touchIMMUNOLOGYtouchimmunology.com
232. Treatment of liver cirrhosis using hepatocyte-derived liver progenitor-like cells: a prospective, open-label, single-arm, safety trialnature.com
233. UCSD Fibrosis Clinical Trials for 2026 — San Diegoclinicaltrials.ucsd.edu
234. UCSF Fibrosis Clinical Trials for 2026 — San Francisco Bay Areaclinicaltrials.ucsf.edu
235. What's the latest update on the ongoing clinical trials related to liver fibrosis?synapse.patsnap.com
236. Liver cirrhosis more common than previously thought, study findssciencedaily.com
237. The Epidemiology of Cirrhosis in the United States: A Population-based Study - PubMedpubmed.ncbi.nlm.nih.gov
238. Prevalence and predictors of cirrhosis and portal hypertension in the United Statesjournals.lww.com
239. Increasing prevalence of cirrhosis among insured adults in the United States, 2012–2018 - PMCpmc.ncbi.nlm.nih.gov
240. Increasing prevalence of cirrhosis among insured adults in the United States, 2012–2018journals.plos.org
241. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019bmcpublichealth.biomedcentral.com
242. Global epidemiology of cirrhosis — aetiology, trends and predictionsnature.com
243. Full article: Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019doi.org
244. The Global Burden of Liver Disease - Clinical Gastroenterology and Hepatologycghjournal.org
245. Increasing prevalence of cirrhosis among insured adults in the United States, 2012–2018ncbi.nlm.nih.gov
246. Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database - Garg - Annals of Translational Medicineatm.amegroups.org
247. Increasing Economic Burden in Hospitalized Patients With... : Clinical and Translational Gastroenterologyjournals.lww.com
248. Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database - PMCpmc.ncbi.nlm.nih.gov
249. Comparing the cost of cirrhosis to other common chronic... : Hepatologyjournals.lww.com
250. Patients Hospitalized for Complications of Cirrhosis may Have Benefited From Medicaid Expansion Under the Affordable Care Act - PMCpmc.ncbi.nlm.nih.gov
251. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 - The Lancet Gastroenterology & Hepatologythelancet.com
252. Full article: Global burden of liver cirrhosis 1990–2019 and 20 years forecast: results from the global burden of disease study 2019tandfonline.com
253. The burden of liver cirrhosis in mortality: Results from the global burden of disease studyncbi.nlm.nih.gov
254. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinomamdpi.com
255. Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years - ScienceDirectsciencedirect.com
256. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinomancbi.nlm.nih.gov
257. Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Eliminationncbi.nlm.nih.gov
258. Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series study - The Lancetthelancet.com
259. Public health policies and alcohol-related liver disease - PMCpmc.ncbi.nlm.nih.gov
260. Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series studyncbi.nlm.nih.gov
261. The impact of alcohol minimum pricing policies on vulnerable populations and health equity: A rapid review - ScienceDirectsciencedirect.com
262. Elimination of hepatitis by 2030who.int
263. Efforts to eliminate hepatitis delivers gains but more action needed to meet 2030 targetswho.int
264. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention - PubMedpubmed.ncbi.nlm.nih.gov
265. Laennec's cirrhosis - The Lancetthelancet.com
266. Laennec's cirrhosistaylorfrancis.com
267. (PDF) Why does cirrhosis belong to Laennec?researchgate.net
268. Why does cirrhosis belong to Laennec?cmaj.ca
269. Breaking the Child-Pugh Dogma in Hepatocellular Carcinomaascopubs.org
270. Child-Pugh Score: Prognosis, Classification & Cirrhosis Staging in Chronic Liver Disease [Classics Series]2minutemedicine.com
271. Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patientscdn.clinicaltrials.gov
272. From Child-Pugh to MELD score and beyond: Taking a walk down memory laneelsevier.es
273. Model for End-Stage Liver Diseaseen.wikipedia.org
274. Why do we use the model for end-stage liver disease (MELD) score?: Part 1aasld.org
275. Laënnec of Laënnec's cirrhosis - Gastroenterologygastrojournal.org